Conditions: Malignant Melanoma Head and Neck Cancer
Keywords: Tissue Hematopoietic Stem Cell Melanoma Squamous Head and Neck Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
The overall goal of this study is to develop a pre-clinical platform of melanoma and head and neck squamous cell cancer that will allow the investigators to learn more about these diseases and discover better and more individualized treatments.

Detailed description:
The main objective of this study is to establish a humanized animal model. Investigators will consent patients who have melanoma and head and neck squamous cell cancer (HNSCC) and agree to take part in this research study. They will obtain peripheral hematopoietic stem cells (HSC), blood and tumor tissue at baseline from blood and tumor samples from these patients for use in establishing tumor explants in humanized mice. Therapy results on humanized mice will be correlated with existing or newly acquired efficacy results from those same immune-based or other therapies in patients. A secondary objective is to identify pharmacodynamic markers associated with each drug and biomarkers for evidence of efficacy or lack of thereof. Where possible, subjects receiving therapy with FDA-approved drugs of interest will be asked to provide sequential blood and tumor biopsies to study the molecular and immune events that may occur as a result of drug therapy.

Arms:
arm 1: 10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days

Interventions: intervention 1: Filgrastim
Intervention descriptions: intervention 1: Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule

Protocol document:
Prot_SAP_ICF_000.pdf: 
COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 1 of 27 
 
Title: 
Pilot Study of Tissue and Hematopoietic/Mesenchymal Stem 
Cell Collection for Humanized Xenograft Studies in Melanoma 
and Squamous Head and Neck Cancer  
 
Institution: 
University of Colorado Cancer Center  
 
Aurora, Colorado 
 
Principal Investigator: 
Antonio Jimeno, MD, PhD 
Associate Professor 
Division of Medical Oncology 
Director, Developmental Therapeutics/Pharmacodynamic Laboratory 
Phone: 303-724-2478 
Fax: 303-724-3892 
Address (mailing):  
P.O. Box 6511, MS 8117 
 
Aurora, CO, 80045  
Address (overnight only): 12801 E. 17th Avenue 
 
RC1 South Room 8106 
 
Aurora, CO, 80045  
Address (laboratory):  
12801 E. 17th Avenue 
 
RC1 South Room 8401G 
 
Aurora, CO, 80045  
 
Co-Investigators: 
 
University of Colorado Cancer Center Surgical Oncologists: 
 
 
 
 
 
Mariah Brown, MD 
John Song, MD 
University of Colorado Cancer Center Medical Oncologists: 
 
 
 
 
 
William Robinson, MD, PhD 
 
 
 
 
 
Rene Gonzalez, MD 
 
 
 
 
 
Daniel Bowles, MD 
Karl Lewis, MD 
Jessica McDermott, MD 
 
 
 
 
University of Colorado at Denver Pathologist 
 
 
 
 
 
Joshua Wisell, MD 
 
Protocol Coordination: 
Cancer Clinical Trials Office (CCTO) and  
 
 
 
 
Dr. Jimeno’s laboratory 
 
Protocol Date:  
 
 June 1, 2017 
 
Amendment:   
 
5 
 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 2 of 27 
BACKGROUND AND RATIONALE 
 
Introduction 
 
We are witnessing a fascinating era for Oncology Drug Development that is presenting us with new 
challenges. In one hand, there are more and more novel targeted therapies, and it is difficult to 
prioritize which drug is most worthy of being clinically tested. In many instances, due to the way the 
drug approval process is currently structured, drugs are taken to human testing with fundamental 
questions unanswered such as the specific target inhibited, the rational combination or the most 
appropriate sequencing strategy. The second major shift is the increasing demand from patients and 
patient advocacy groups for more personalized treatment strategies, that is, figuring out early in the 
drug development process what the determinants of response or clinical benefit to new (and 
established) drugs are. These questions are becoming more complicated as a plethora of new 
targets and new drugs are discovered, and it would be impossible (and also perhaps unethical) to 
find enough patients to answer all of these issues in a clinical setting. Currently, it takes over a 
decade, and over $800,000,000, to develop a drug. The basic tool for early drug development is the 
use of cell lines derived from tumors after hundreds of passages on artificial and simplified systems. 
Drugs are tested in cell lines, and then go straight to toxicology studies and human testing in phase 
I. There is plenty of evidence that cell lines are not predictive of what occurs is a much more complex 
system such as a patient. Additionally current models lack a human immune system, and the 
development of humanized models is an area of intense work. Unsurprisingly, nine out of ten drugs 
fail during this laborious, lengthy, and expensive process, and even those that pass work in only 10-
20% of cancer patients and provide highly marginal clinical benefits of a few weeks/months of 
survival. New approaches should be explored using models that are closer to the complexities of a 
patient’s tumor.  Such a system, as described here, is considered one of the most promising of the 
novel approaches being explored. 
 
The overall goal of this study is to develop a preclinical platform of melanoma and head and neck 
squamous cell cancer (HNSCC) that will allow us to learn more about these diseases and discover 
better and more individualized treatments. The principal investigator of this protocol has successfully 
accomplished this in other cancers (such as pancreatic, HNSCC, salivary gland and squamous skin 
cancer).  
 
We implant tumors in mice because from a very small sample of tissue we can generate a much 
greater amount of tumor, which can be used for complex testing not possible with the small, original 
human sample. When they grow, the tumors will be expanded and maintained alive on mice so that 
we can conduct biological analyses and test anticancer drugs (some approved and in regular use, 
some investigational). We will learn whether there is a correlation between what happens in the 
patient and what happens in the patient’s tumor in mice. From this we hope to learn what predicts 
that a patient will benefit, as we expect that some tumors will be sensitive and others resistant to 
each of the agents, and we will be able to identify those differential features. This will allow us to 
design and test individualized therapies for melanoma and HNSCC cancer in a model as close as 
possible to the clinical setting, thus likely preventing patients being enrolled in clinical trials with drugs 
that would be ultimately ineffective.  
 
Melanoma 
 
Melanoma causes over 8700 deaths per year in the US. Even though several small molecule 
targeted therapies and paradigm-changing immune modulatory agents (ipilimumab, nivolumab, 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 3 of 27 
MK3475) have been developed recently (1-5), there are many unanswered questions: first, we do 
not understand how to individualize immune therapy for melanoma; second, we do not fully 
understand the molecular basis of immune response; third, we lack understanding of the interaction 
of immune therapies and the stroma; and finally, it is likely that there are many undiscovered immune 
targets. 
 
Head and Neck Cancer 
 
Head and neck squamous cell carcinoma (HNSCC) remains a devastating disease. The estimated 
combined yearly incidence in the USA is well over 50,000 new cases with over 13,000 expected 
deaths (6). In most instances advanced (widespread or metastatic) HNSCC or SGC is incurable, 
especially disfiguring and uniformly fatal. Despite a lowering tobacco consumption in recent years 
HNSCC incidence has not decreased and affects an increasingly younger population, due to an 
epidemiology shift caused by the involvement of human papilloma viruses (HPV) in their 
pathogenesis (7). Therefore we can only expect this disease to be a more relevant health problem 
in the next decades. SGC incidence remains stable. 
 
When discovered early HNSCC has a good chance of being cured, but when it is advanced or recurs, 
the prognosis is very poor, being as it is a particularly disfiguring cancer. Only one agent (cetuximab) 
has been added to its treatment in the last 10 years (8), but the benefit is limited in intensity and in 
the proportion of patients that achieve it. Overall, no major advances have occurred for HNSCC 
patients in the last 10 years, and this is partly because there are no good preclinical models of 
HNSCC to study new drugs and/or new ways to deliver the right drug to the right patient. This clinical 
protocol is aimed at rationally generating a tool to achieve that greater goal.  
 
Direct xenografting of patient tumors as a preclinical model for Drug Development 
 
Freshly generated xenografted tumors have the potential to recapitulate more closely the biology of 
cancer than existing cell lines and are a better discriminator of the activity of anticancer drugs. The 
principal investigator has been involved in the generation of the largest academic mouse colony in 
the US, with over 200 pancreatic cancer patients consented and 80 cases successfully growing (9, 
10). In addition, the PI generated a colony of 10 squamous skin cancers after implanting 15 cases 
of locally advanced lip, nose and face origin, highlighting the high take rate of epidermoid histologic 
strains (in addition to adenocarcinomas). This has allowed a variety of studies including: 
 
1. Development of novel diagnostic techniques: fine-needle aspiration (FNA) biopsy for drug 
pharmacodynamic monitoring (11) -> this is being tested in the clinic. 
2. Early new drug development: testing of novel, academically-developed anticancer agents 
(12) -> this agent is being tested in the clinic in Phase I. 
3. Complementing clinical trials: developing strategies to bridge the clinic and the laboratory 
(13). 
4. Rational combination drug studies: testing combinations of established and 
investigational agents (14, 15) -> this generated two separate hypothesis that are being 
tested in the clinic (both at UCHSC). 
5. Biomarker development: devising ways to individualize therapy by mining for biomarkers 
(16) -> this is being tested in the clinic in Phase II. 
 
The common denominator of these strategies is that the laboratory findings were very rapidly 
translated to the clinic, so these advancements have the potential to benefit our patients sooner. 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 4 of 27 
Another aspect is that the solidity of the data has allowed the generation and licensing of over 10 
reports of invention and patents, highlighting the interest this strategy raises in the drug development 
field. 
 
A fundamental question is whether the xenografts predict what occurs in the patient, and whether 
one could possibly guide patient therapy based on xenograft data. The principal investigator of this 
study has also been an instrumental part in the clinical trial that aimed at prospectively validating this 
model clinically in pancreatic cancer at Johns Hopkins (ASCO 2008, oral presentation). In that study 
patients were consented preoperatively and their tumors were xenografted and tested with a panel 
of FDA-approved agents (9). In 2 years over 200 patients were consented, and over 60 cases were 
successfully xenografted out of 110 implantations. This highlights the expertise, and the feasibility of 
this approach. In Figure 1 we can see an example (case JH033). This patient was found in the 
xenograft study to be resistant to gemcitabine and sensitive to mitomycin C. Unfortunately, the 
patient progressed prior to this data being available (with a baseline CA199 of 21,000), and received 
single-agent gemcitabine. He developed disease progression (with a CA199 two months later of 
98,400). At that point the data became available, and the patient was treated with mitomycin C. He 
received 6 cycles of drug, showing clinical benefit (ECOG went from 1 to 0), a partial response 
radiographically, and a complete response by marker (his CA199 has dropped without a plateau to 
date to <40). Prior to starting MMC, the patient was declared refractory and hospice care was being 
discussed; on MMC he has so far been 2 years free of progression and resumed his job full-time. 
Though the clinical significance of this strategy remains to be proven, as more patients need to be 
considered, this encourages us in that these models are predictive of clinical activity of drugs, and 
therefore they may be more relevant for new drug development than the models currently in use.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PURPOSE AND OBJECTIVES 
 
The primary objective of this study is to establish a humanized animal model. To this end, we will 
obtain peripheral hematopoietic/mesenchymal stem cells (HSC), blood and tumor tissue at baseline 
from blood and tumor samples from patients with melanoma and HNSCC who participate in the 
protocol at the University of Colorado Denver/University of Colorado Hospital for use in establishing 
tumor explants in humanized mice. Therapy results on humanized mice will be correlated with 
existing or newly acquired efficacy results from those same immune-based or other therapies in 
patients.  
Diagnosis 
Gemcitabine 
Mitomycin C 
Figure 1. Left: JH033 xenograft data, where gemcitabine shows no effect and mitomycin C shows 
profound antitumor efficacy. Right: Clinical course of patient JH033, where the patient progresses 
on gemcitabine but has a complete response to mitomycin as judged by CA-199.  
0
20
40
60
80
100
120
Control
Gemcitabine
MMC
Growth (% normalized to control)


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 5 of 27 
 
The secondary objective is to identify pharmacodynamic markers associated with drugs and 
biomarkers predictive of efficacy (or lack of thereof). To this end, and where possible, patients 
receiving therapy with Food and Drug Administration (FDA)-approved drugs of interest will be asked 
to provide sequential blood and tumor biopsies to study the molecular and immune events occurring 
as a result of therapy.  
 
An exploratory objective is to assess the logistic feasibility of humanized mice to prospectively guide 
patient therapy decisions. To this end, the information obtained from testing the humanized mice 
with anti-melanoma drugs of interest may be used, at the patient’s physician discretion, to guide 
his/her future therapy, in the context of FDA-approved indications, and/or in the context of a clinical 
trial, in both instances under a separate informed consent. Based on our experience, it can take 
between 3 and 6 months from obtaining the HSC until drug efficacy studies are complete, and 
therefore this warrants direct therapy guidance to be limited to an exploratory setting. 
 
ELIGIBILITY CRITERIA 
 
Inclusion criteria 
 
1. Biopsy proven incurable melanoma or incurable HNSCC amenable to have biopsy and/or 
surgical resection of either the primary and/or locoregional metastatic site, at the University 
of Colorado Hospital.  
 
2. Age ≥ 21 years old (per NCI/NIH guidelines). 
 
3. ECOG performance status of 0, 1, or 2 
 
4. Adequate bone marrow, hepatic and renal function: 
- 
Absolute neutrophil count ≥ 1,500/µL. 
- 
Platelets ≥ 100,000/µL. 
- 
Hemoglobin ≥ 9.0 g/dL. 
- 
Creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥ 
60mL/min. 
- 
Total bilirubin ≤ 1.5x ULN. 
- 
AST/ALT ≤ 2x ULN.  
 
5. Measurable disease according to investigator.  
 
6. O2 saturation ≥ 93% at room air. 
 
7. Ability to understand and willingness to sign a written informed consent document. 
 
Exclusion criteria 
 
1. Contraindication (absolute or relative) to granulocyte colony-stimulating factor (G-CSF; 
filgrastim) usage:  
- 
known hypersensitivity to E coli-derived proteins‚ filgrastim, or any other component 
of the product.  
- 
Sickle cell disorders. 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 6 of 27 
- 
Clinically significant and active lung hemorrhagic or inflammatory disease, including 
but not limited to COPD, autoimmune disease, and alveolar hemorrhage; or 
hypoxemia of any etiology requiring oxygen. 
- 
Clinically significant splenomegaly or splenic metastases; history of splenic rupture, 
recent splenic trauma or other clinically significant splenic disease that increases the 
risk of splenic rupture. 
 
2. Clinically significant and active malignancy other than incurable melanoma or head and neck 
squamous cell cancer. 
 
3. Known hepatitis B or C, or HIV. 
 
INFORMED CONSENT 
 
Patients with incurable melanoma or incurable HNSCC from the University of Colorado Hospital will 
be asked to participate in the study. Subjects will be consented by qualified study personnel, i.e., a 
research coordinator and/or investigator. These personnel will understand the research study and 
will have completed a COMIRB education course as directed by institutional requirements. The 
investigators, clinic nurses or research coordinator will provide the subject with information regarding 
the research study.  
 
Consent will be obtained in a quiet setting prior to the initiation of any study procedures and the 
subject will be given ample time to consider the consent form and ask questions. Every effort will be 
made to ensure that the patient has an understanding of the consent formed based upon his or her 
verbal responses. Qualified personnel, prior to the initiation of study procedures, will obtain written 
consent from the eligible patient. For non-English speaking subjects, verbal translation of the consent 
will be provided onsite and all applicable procedures will be followed as outlined by COMIRB. The 
subjects will receive a signed and dated copy of the consent form.   
 
STUDY EVENTS 
 
Study Design 
 
This is a study where incurable melanoma and HNSCC patients are consented to receive G-CSF in 
order to harvest 1) peripheral hematopoietic/mesenchymal stem cells (HSC) and blood, 2) tumor 
tissue, and 3) optional sequential harvests of blood and tumor samples while on anti-melanoma or 
anti-HNSCC therapy. The HSC will be infused into mice either freshly obtained or after stabilization 
in the lab to generate humanized mice.  After engraftment, tumor tissue from the same patient will 
be implanted. Typically, it takes 4-8 weeks for HSCs to engraft and give rise to humanized mice, so 
there will be a lag between patient G-CSF administration/HSC collection and patient tumor biopsy 
implantation. These humanized mice will be studied and tested with drugs in current use for 
melanoma and HSNCC. Where possible, patients receiving therapy with FDA-approved drugs of 
interest will be asked to provide sequential blood and tumor biopsies to study the molecular and 
immune events occurring as a result of therapy.  
 
This design is optimal to test the objectives of this project: The primary objective of this study is to 
establish humanized mice, and determine the correlation between the efficacy of immune-based and 
other therapy in patients and in their corresponding humanized mice. The secondary objective is to 
identify correlative and predictive biomarkers associated with each drug. Where possible, patients 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 7 of 27 
receiving therapy with FDA-approved drugs of interest will be asked to provide sequential blood and 
tumor biopsies. An exploratory objective is to assess the logistic feasibility of humanized mice to 
prospectively guide patient therapy decisions. To this end, the information obtained from testing the 
humanized mice with anti-melanoma drugs of interest may be used, at the patient’s physician 
discretion, to guide his/her future therapy, in the context of FDA-approved indications, and/or in the 
context of a clinical trial (in both instances under a separate consent). 
 
Tumor, cell line generation  
 
We will acquire normal and tumor tissue, as well as blood samples from patients. We will generate 
cell lines from this tissue that can include (but are not limited to): 
- 
Cancer lines (including but not limited to cell lines and xenograft lines, if feasible). 
- 
Blood progenitor lines (including but not limited to HSCs, PBMC, and other blood-
derived progenitor lines, if feasible). 
- 
Normal tissue lines (including but not limited to fibroblast, macrophages, if feasible) 
 
These lines and models will be used for studies including but not limited to biology 
characterization, genetic characterization, and drug studies. 
 
Study Event Summary 
 
Events 
Time point 
 
 
 
    
 
1 - Identification and Screening 
D -14 to D -1 
 
2 - Baseline 
• 
Whole Blood for Genomic Testing 
Prior to G-CSF Admin. 
• 
G-CSF Administration 
D1 to D4 
• 
CBC, CMP, and AE Assessment  
D6 to D7 (+/- 1 day) 
• 
HSC Harvest 
On D6 and on D7 (+/- 1 day) 
• 
30 Days Post-Harvest AE Assessment 
D35 to 42 
 
3 - Primary Tumor Biopsy 
Before, at HSC Harvest or after 
• 
Circ. B and T cell blood sample 
At the time of biopsy 
 
4 - Optional: Sequential Harvests for Subsequent Therapies 
 
• 
Sequential Blood Sample #1 
Prior to Day 1 of New Therapy 
• 
Sequential Tumor Biopsy #1 
Prior to Day 1 of New Therapy 
 
Note: Sequential Blood Sample #1 and Tumor Biopsy #1 are not required if no 
intervening therapy has occurred  
• 
Sequential Blood Sample #2, #3, etc. 
Day 21, 42, etc. of New Therapy 
• 
Subsequent Tumor Biopsy #2 
Day 21 of New Therapy 
 
Study Event Details 
 
1 – Identification and Screening 
 
Patients whom are candidates for this study will be evaluated, screened, enrolled, and followed-up 
at the University of Colorado Cancer Center. Informed consent will be obtained from all qualifying 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 8 of 27 
patients and will be obtained by the principal investigator, a co-investigator, or a designee for this 
study. 
 
Screening will consist of: 
- 
Informed consent. 
- 
History, physical exam, vital signs, O2 saturation, concomitant medications, and 
presence/grading of adverse events at baseline. 
- 
Laboratories:  
o CBC (WBC, ANC, Hb, platelets, volume parameters, formula) and, 
o CMP (Na, Cl, K, Cr, BUN, AST/SGOT, ALT/SGPT, Alk. Phos., Protein, Albumin). 
 
2 – Baseline 
 
Whole Blood Collection for Genomic Testing 
 
A baseline 10 mL sample of whole blood for genomic testing will be collected.  
 
G-CSF Administration 
 
Patients will then receive 10 µg/kg/day of filgrastim subcutaneously on a 4-day mobilization 
schedule. Filgrastim will be purchased at the UCH Pharmacy and provided by the study at no cost 
to the patient (like all other study-specific procedures). The patient will be supplied with instructions 
for self-administration, or administration will be arranged in clinic for them. 
 
HSC Harvest 
 
At the time of HSC harvest (+/- 2 days), we will draw blood for a CBC and a CMP, and conduct a 
follow up clinical and Adverse Event (AE) assessment with the subject. 
 
Blood collection for HSC harvesting will occur on days 6 and 7, until a sufficient number of HSC are 
collected (at least 2 x 106), by means of a peripheral blood draw of 100 mLs of blood each day. This 
collection timeline will have a window of +/- 1 day. This will take place in clinic and conducted by 
appropriate personnel. In our experience, one draw yields 100,000 to 200,000 CD34+ HSC cells per 
10 mL of peripheral blood. Thus, with a blood draw of 100 mL we expect to harvest 1 x 106 to 2 x 
106 cells. We aim at obtaining at least 2 x 106 HSCs. 
 
After HSC isolation, they will be infused into mice intravenously either immediately or after 
stabilization in the laboratory, or both. It has not been established which is the optimal method. Within 
this protocol we will explore various laboratory techniques to improve HSC harvest, yield, 
engraftment efficiency, use as allogeneic controls, and humanization to use as syngeneic hosts. We 
will also keep a sample from each patient cryopreserved.  
 
Typically it takes 4-8 weeks for HSCs to engraft in mice and give rise to humanized mice, so there 
will be a lag between patient G-CSF administration/HSC collection and patient tumor biopsy 
implantation. 
 
 
 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 9 of 27 
30 Days Post-Harvest Clinical (AE) Assessment 
 
Approximately 30 days later (day 35 to 42) we will conduct a second clinical and AE assessment 
either over the phone or in person by the PI or a delegated co-investigator. 
 
3 – Primary Tumor Biopsy 
 
Primary Tumor Biopsy 
 
The Primary Tumor Biopsy may occur at the time of the HSC collection, or may occur at a later time. 
The patient will undergo an excisional or core biopsy of the most accessible lesion in the opinion of 
the ENT or Cutaneous Cancer clinical providers. We will require a minimum size of 3 x 1 mm. The 
sample will be immediately implanted on a cohort of up to 5 mice.  
 
Blood Collection for Circulating B and T Lymphocytes  
 
At the time of the Primary Tumor Biopsy, a 10 mL blood sample will be drawn to determine the 
circulating B and T lymphocyte distribution.  
 
The requirement of the tumor biopsy may be waived if the patient has already participated previously 
in a tissue banking protocol and a tumor line/xenograft is already established in the Jimeno 
Laboratory.   
 
4 – Optional: Sequential Harvests for Subsequent Therapies 
 
When the patient starts an FDA-approved anticancer treatment deemed to be of relevance by the 
study PI to the humanized model (including but not limited to immunotherapies, such as ipilimumab, 
nivolumab, and/or pembrolizumab), the patient will be asked to provide optional sequential blood 
samples (every 21 days after treatment initiation) and tumor samples (twice: once before new 
therapy and once 21 days after initiation therapy). 
 
This sequential blood sample and tumor biopsy collection process will occur for each treatment 
regimen deemed to be of relevance by the study PI. 
 
If no intervening therapy has occurred since the time of the Primary Tumor Biopsy, another baseline 
biopsy and blood draw will not be needed.  
 
A separate informed consent process will occur for subsequent tumor biopsies and blood sample 
collections, as these procedures and assessments are part of the secondary and/or exploratory 
objectives of the study. Sequential biopsiable sites can include not only skin lesions, but also other 
sites that according to the treating physician are safely accessible (nodes, liver lesions), and that 
conform to the Institution’s safety guidelines for sequential tumor biopsies. Thus for every therapy 
we will establish a (prospective or retrospective) correlation with humanized mice therapy efficacy 
and correlative studies.  
 
 
 
 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 10 of 27 
METHODS 
 
Generation of Tumor Explants 
 
Aliquots from the resected tumor specimen will be implanted in nude mice using standard 
procedures developed by the principal investigator as detailed in the animal protocols entitled 
Generation of a cancer direct xenograft colony with primary and metastatic tumors.   
 
Collection, Processing, and Purpose of Blood and Tissue 
 
Note: Please use collection and processing instructions in Appendix A. 
 
Whole Blood for Genomic Testing 
 
Timepoint:  
Prior to G-CSF Administration 
Purpose:  
This will be used for genomic DNA testing, and for unforeseen biomarker studies in 
the future. The study will analyze the different normal cells as well as their protein 
and genetic (including but not limited to mRNA, miRNA, methylation, DNA) profiles. 
This will be correlated to the same analyses in tumor cells to establish changes and 
correlations to help understand cancer generation and progression. 
 
Whole Blood for HSC Harvesting 
 
Timepoint:  
On D6 and on D7 (+/- 1 day) 
Purpose:  
This will be used for HSC isolation, to use in humanization of mice, and for 
unforeseen biomarker studies in the future. The study will analyze the different 
normal and potentially tumor cells and cell lines as well as their protein and genetic 
(including but not limited to mRNA, miRNA, methylation, DNA) profiles. This will be 
correlated to the same analyses in normal and tumor cells to establish changes and 
correlations to help understand cancer generation and progression, as well as 
the role of the immune system in cancer. The cells may be propagated as 
isolated or after modification. 
 
Blood Sample for Circulating B and T Cell Distribution 
 
Timepoint:  
At the time of primary tumor biopsy 
Purpose:  
This will be used to determine the circulating B and T lymphocyte distribution.  
 
Tumor Biopsy 
 
Timepoint:  
At the time of HSC Harvest or beyond 
Purpose:  
The study will analyze the different tumor cells as well as their protein and genetic 
(including but not limited to mRNA, miRNA, methylation, DNA) profiles in normal 
and tumor tissue. The overall purpose of these studies is to determine the 
differences in terms of cell populations and signaling, and to learn about the 
mechanisms that allow cancer cells to survive treatment. 
 
 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 11 of 27 
Optional Sequential Blood Samples 
 
Timepoint:  
Prior to C1D1 of new treatment, then every 21 days thereafter (+/- 2 days) 
Purpose:  
These samples will be used to study the molecular and immune events occurring as 
a result of therapy. 
 
See Appendix A for detailed tissue and blood collection, handling, and processing instructions. 
Tissue samples collected will be stored frozen and in the mouse live bank indefinitely. 
 
Optional Tissue Collection from Standard of Care Procedures 
 
Subjects whom agree to participate in the initial part of the study will be asked to again donate 
tumor tissue at a later timepoint. The patient may consent to allow our team to collect additional 
tumor tissue if the subject is scheduled for any additional biopsies or resections as part of their 
regular clinical care for HNSCC or melanoma. This optional collection is outlined as an optional 
provision in the Main Informed Consent Form. If the patient opts to donate excess tissue from 
future procedures, the following samples will be collected: 
 
Collection:  
Donated excess tissue from any additional scheduled biopsies or resections, as part 
of his/her regular clinical care for HNSCC or melanoma. 
 
Processing:  See Appendix A. Tissue samples collected may be implanted in mice in the Jimeno 
Lab following the established protocol. Tissue samples will be stored frozen and 
paraffin-embedded, and kept alive in the mouse live bank and as cell lines 
indefinitely.  
 
Purpose:  
The study will analyze the different tumor cells as well as their protein and genetic 
profiles, and the tissue may be implanted in mice; these are identical to the testing 
conducted in the original sample. The overall purpose of these studies is to 
determine the differences in terms of cell populations and signaling, to learn about 
the mechanisms that allow cancer cells to survive treatment. 
 
See Appendix A for tissue handling and processing instructions. Tissue samples collected will be 
stored frozen and in the mouse live bank indefinitely. 
 
Optional Research Tumor Biopsy 
 
Subjects who agree to participate in the initial part of the study will be asked to again donate tumor 
tissue at a later timepoint. If the subject is NOT scheduled for any additional biopsies or resections 
as part of their regular clinical care for HNSCC or melanoma, they will be asked to participate in a 
Research Tumor Biopsy. The Optional Research Tumor Biopsy will take place after a separate 
optional informed consent is obtained (see independent Research Biopsy Informed Consent). After 
optional informed consent is obtained, the following samples will be collected: 
 
Collection:  
Core biopsy of tumor areas, with radiologic guidance with ultrasound if required.  
 
Processing:  See Appendix A. Tissue samples collected may be implanted in mice in the Jimeno 
Lab following the established protocol. Tissue samples will be stored frozen and 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 12 of 27 
paraffin-embedded, and kept alive in the mouse live bank and as cell lines 
indefinitely.  
 
Purpose:  
The study will analyze the different tumor cells as well as their protein and genetic 
profiles, and the tissue may be implanted in mice; these are identical to the testing 
conducted in the original sample. The overall purpose of these studies is to 
determine the differences in terms of cell populations and signaling, to learn about 
the mechanisms that allow cancer cells to survive treatment. 
 
See Appendix A for tissue handling and processing instructions. Tissue samples collected will be 
stored frozen and in the mouse live bank indefinitely. 
 
RECRUITMENT 
 
Up to 40 patients locally will be recruited from the investigators’ clinic at the University of Colorado 
Cancer Center. This figure is based on the goal to have 15 successful engrafting cases to enable 
meaningful biologic characterization and drug testing.  
 
The justification for the number of successful cases required is as follows. 
Since the feasibility of establishing humanized mice has not been tested prospectively, this pilot 
study will explore this feasibility. Since participation in this study requires patients to receive 
GCSFs and undergo a study-related biopsy, which are associated with more risk than minimal, we 
aimed at keeping enrollment in this pilot study at the minimum. If this study proves feasible, the 
sample size may be increased at a later time to enable full efficacy testing and patient outcomes 
correlations, for instance. However, at this pilot stage such studies are not feasible, and thus the 
sample size is largely dictated by the PI’s experience with regard to the minimum sample size to 
determine if humanizing and conducting drug testing prospectively is a feasible strategy. 
 
Based on the PI’s experience, we do not anticipate problems of tumor availability since patients will 
be selected based on their willingness to undergo a biopsy and the existence of enough disease to 
be safely and effectively sampled. Likewise, mobilization has a greater than 95% success rate both 
in prior studies as well as in other settings where mobilization is standard. Therefore, we do not 
anticipate attrition from inability to obtain HSCs. However, of those engrafted, 75% are a 
success (defined as growth sufficient to passage further in < 6 months, and ability to be viably 
passaged at least three times). Thus, we will consent 20 patients per disease site (20 melanoma, 
20 HNSCC) to obtain sufficient engrafted cases.  
 
Protected health information (PHI) can be accessed by the investigators and their clinical staff or 
designee(s). There will be no study specific patient advertising or supplemental recruitment 
materials used for this study. The study will not exclude potential subjects from participation on the 
basis of ethnic origin or gender. Subjects recruited will include men, women and all ethnic origins, 
provided they meet all eligibility criteria.   
 
DURATION OF THE STUDY 
 
It is anticipated that this study will take up to 5 years to complete. 
 
 
 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 13 of 27 
DISCOMFORTS AND RISKS, AND MANAGEMENT OF RISKS 
 
The following section includes descriptions of potential risks, including risks to confidentiality. 
 
G-CSF Administration 
 
The risks associated with G-CSF administration in the context of mobilizing patients that are not 
neutropenic and are not actively receiving chemotherapy but that received filgrastim for peripheral 
blood progenitor cell (PBPC) collection are summarized from filgrastim’s FDA label: 
 
In clinical trials‚ 126 patients received filgrastim for PBPC mobilization. In this setting‚ filgrastim was 
generally well tolerated. Adverse events related to filgrastim consisted primarily of mild-to-moderate 
musculoskeletal symptoms‚ reported in 44% of patients. These symptoms were predominantly 
events of medullary bone pain (33%). Headache was reported related to filgrastim in 7% of patients. 
Transient increases in alkaline phosphatase related to filgrastim were reported in 21% of the patients 
who had serum chemistries measured; most were mild-to-moderate. 
 
All patients had increases in neutrophil counts during mobilization‚ consistent with the biological 
effects of filgrastim. Two patients had a WBC count > 100‚000/mm3. No sequelae were associated 
with any grade of leukocytosis. Sixty-five percent of patients had mild-to-moderate anemia and 97% 
of patients had decreases in platelet counts; five patients (out of 126) had decreased platelet counts 
to < 50‚000/mm3. Anemia and thrombocytopenia have been reported to be related to leukapheresis; 
however‚ the possibility that filgrastim mobilization may contribute to anemia or thrombocytopenia 
has not been ruled out. 
 
Other generic (not restricted to a PBPC setting) potential side effects of filgrastim include: 
• 
Allergic Reactions. Allergic-type reactions occurring on initial or subsequent treatment have 
been reported in < 1 in 4000 patients treated with filgrastim. These have generally been 
characterized by systemic symptoms involving at least two body systems‚ most often skin 
(rash‚ urticaria‚ facial edema)‚ respiratory (wheezing‚ dyspnea)‚ and cardiovascular 
(hypotension‚ tachycardia). Some reactions occurred on initial exposure. Reactions tended 
to occur within the first 30 minutes after administration and appeared to occur more frequently 
in patients receiving filgrastim IV (which is not the route we will utilize in this protocol). Rapid 
resolution of symptoms occurred in most cases after administration of antihistamines‚ 
steroids‚ bronchodilators‚ and/or epinephrine. Symptoms recurred in more than half the 
patients who were re-challenged. 
• 
Splenic rupture. Splenic rupture, including fatal cases, has been reported following the 
administration of filgrastim. Individuals receiving filgrastim who report upper left abdominal 
and/or shoulder tip pain should be evaluated for an enlarged spleen or splenic rupture. 
• 
Acute Respiratory Distress Syndrome (ARDS). Acute respiratory distress syndrome (ARDS) 
has been reported in patients receiving filgrastim, and is postulated to be secondary to an 
influx of neutrophils to sites of inflammation in the lungs. Patients receiving filgrastim who 
develop fever, lung infiltrates, or respiratory distress should be evaluated for the possibility of 
ARDS.  
 
Tissue Sample Collection(s) 
 
From the perspective of the primary objective of this study that is acquiring tumor tissue there is a 
relatively low risk from participation in this study as the subjects as typically melanoma deposits allow 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 14 of 27 
tumor acquisition with relatively low morbidity from superficial lesions. The risks associated with 
these procedures are infection, lack of wound healing, and local tumor spread. Tissue will only be 
obtained from sites that the ENT and Cutaneous Cancer Clinic physicians deem appropriate and 
feasible.  
 
There is a risk that the tissue will be used up in the research activities and for some unforeseen 
medical reason would be needed in the future, although the biopsy is not done for diagnostic 
purposes since a diagnosis is already established.  
 
Blood Sample Collection(s) 
 
The risks of a blood sample are minimal and include pain, bleeding, bruising, infection, and skin 
irritation (from cleaning agents used to sterilize the skin, or bandages). 
 
Transmissible Disease 
 
A potential risk to clinical and laboratory study personnel is to be accidentally infected with a 
transmissible disease while manipulating tissue from the patient (initially, or in the laboratory studies). 
 
Specific Anti-melanoma or Anti-HNSCC Therapies 
 
The risks derived from receiving therapy for advanced melanoma or HNSCC are not discussed 
herein, since this is not a therapeutic trial, and the correlation of efficacy between the animal model 
and the clinic does not require prospective therapy (it could theoretically be established fully based 
on past therapeutic effect in the patient). Thus, any prospective therapy decision will be made by the 
primary physician who will contextualize the humanized mice efficacy profile, and will be made either 
in the setting of a FDA-approved administration as standard of care (SOC; associated with a regular 
SOC consent process), or under the aegis of a clinical trial (where a specific consenting will be 
required). 
 
Risk Avoidance and Management 
 
The following section includes description of procedures for protecting or minimizing potential risks 
including risks to confidentiality. 
 
Patients will be carefully screened to ensure meeting all eligibility criteria. The screening criteria and 
study processes have been carefully designed to identify and avoid the known potential adverse 
events resulting from filgrastim in the PBPC setting, and also include other more generic 
contraindications to ensure subject safety. Patients that are not stable clinically, whose organ 
function is not appropriate, or who have prior conditions that put them at risk from filgrastim 
complications (such as lung inflammatory disease, sickle cell disease, splenomegaly or splenic 
abnormalities) will be excluded. After enrolment, patients will be carefully followed by clinical and 
study personnel to ensure that no complications arise from G-CSF administration, tumor biopsy, or 
blood draws.  We will conduct laboratory (CBC, CMP) and clinical and AE assessment approximately 
one week after filgrastim administration, and then clinical assessment approximately 30 days after 
filgrastim administration. 
 
From the perspective of the primary objective of this study that is acquiring tumor tissue there is a 
relatively low risk from participation in this study for the subjects as melanoma deposits typically 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 15 of 27 
allow tumor acquisition with relatively low morbidity from superficial lesions, and HNSCC also 
spreads superficially to easily biopsiable node sites. Tissue will only be obtained from sites that the 
ENT and/or Cutaneous Cancer Clinic physicians deem appropriate and feasible. Standard of care 
post biopsy procedures will be followed to that effect, and there is sufficient clinical personnel and 
sufficient effort allocated from them to achieve this careful surveillance. 
 
Regarding the risk that the tissue will be used up in the research activities, this risk is minimized 
since no usage is made of existing specimens used for clinical diagnosis, and because a trail of 
cryopreserved and paraffin fixed materials are generated. 
Regarding the risk of transmissible disease in clinical or laboratory study personnel, risk is minimized 
since patients with known hepatitis B or C, or HIV are excluded from the study. 
 
Clinical Information on study subjects will be entered in a password-protected clinical trial 
management system, which is a remote, firewalled system used for clinical trials at the University of 
Colorado. Clinical Research Assistants (CRA) are given access to specific protocol data only after 
special training, and each CRA has a specific login and password. Clinical data on study subjects 
will be maintained on this system.  
 
All data and study records including hard copies and computer files will be considered confidential 
and disclosure to third parties other than those listed on the HIPAA Authorization form is prohibited. 
Subjects will be assigned a tissue collection number (specimen number).  The utmost precautions 
will be taken to ensure that PHI is not compromised. Files on the computer are password protected 
and security is maintained by firewalls. Files containing patient data will be stored in a locked office.   
 
Discussion of why the risks to subjects are reasonable in relation to the anticipated benefits 
to subjects and in relation to the importance of the knowledge that may reasonably be 
expected to result. 
 
The only anticipated benefits for the subjects for participating in this study is to learn about the 
susceptibility of their tumor to one or more available therapies for melanoma and HNSCC, which 
while it may or may not correlate with the clinical susceptibility, may inform the patient’s physician 
about the therapy’s potential efficacy. However, as the risks are moderate (bone discomfort from 
filgrastim administration, local pain from the biopsies, bruising from the optional blood sample among 
the major risks involved) we feel this is balanced. 
 
WITHDRAWAL 
 
Participation in this study is voluntary. At any time, the patient may withdraw participation. They must 
contact the principal investigator in writing. The patient’s options would then be to destroy all 
identifying links between the patient and their tissue, and/or have their clinical tissue sent back to the 
original institution if any remains. 
 
BENEFITS 
 
There is no direct benefit to subjects for their participation in this study. However, therapeutic testing 
in humanized mice may identify a therapy for which the patient may be a candidate in the future 
(either as SOC if FDA-approved or in a clinical trial) that either works or does not work, and the 
patient’s oncologist may help inform future treatment based on this information. 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 16 of 27 
 
DATA ANALYSIS 
 
The following is a non-exhaustive list including information that will be gathered at the time of study 
initiation: 
 
1.  Demographic information including: 
 
 
Name  
 
 
Medical record 
 
 
Social Security Number 
 
 
Telephone Number 
 
 
Address 
 
 
Date of birth 
 
 
Date of diagnosis 
 
 
Race/ethnicity 
 
 
Gender 
 
2.  Pathologic diagnosis and specimen number 
 
3.  Prior cancer history, prior therapy, duration of therapy and best response to therapy 
 
4.  Comorbidities 
 
5.  Prior Cancer 
 
6.  Stage of Cancer 
 
7.  Metastatic sites 
 
8.  Site where specimen obtained and designation whether primary or metastatic site 
 
The following is a non-exhaustive list including information that will be collected prospectively: 
 
1.  Outcome information such as: 
 
 
Adjuvant therapy and dates  
 
 
Relapse and dates 
 
 
Therapy in the salvage setting, dates and response 
 
 
Therapy in the advanced setting, dates and response 
 
 
Exitus and dates 
 
2.  Long-term events and toxicities 
 
STATISTICAL PLAN 
 
For reporting purposes, the results will be summarized using standard descriptive statistics. Patient 
baseline and outcome data (in patients consenting specifically for this) will be analyzed as follows: 
Overall survival and progression free survival will be estimated using the Kaplan-Meier method and 
will be displayed graphically. Median overall survival and confidence limits will be determined. 
Kaplan-Meier estimates of survival at 6 and 12 months and their standard errors will be calculated. 
The response rate (if the patient receives therapy in the advanced setting, and disease is amenable 
to being evaluated) will be determined using the RECIST criteria. Comparisons between categorical 
groups will be conducted using the appropriate parametric or non-parametric statistical test (Chi-
square, T-Student, etc.). 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 17 of 27 
In order to establish the correlation between disease characteristics, engraftment success, and 
association with outcome measures (both in the patient and in the xenograft) a multivariate Cox 
model will be constructed.   
 
The correlation between the efficacy of treatments in the xenografts and in patients (if that data 
exists) will be examined both as 1) a “population”-based using Spearman’s and/or Pearson’s tests, 
and 2) as a paired analysis between the efficacy in the patient and in his/her xenograft. For the 
correlation analyses, both the continuous response data (as % following RECIST) and the 
categorical response data (as YES/NO) will be analyzed and included in the multivariate model. 
 
The animal protocol entitled Generation of a cancer direct xenograft colony with primary and 
metastatic tumors has an appropriate and independent statistical plan in order to rationally plan the 
number of animals required. 
 
All statistical analyses will be conducted using an adequately licensed commercial statistical 
package. 
 
DATABASE 
 
A database will be developed to link pertinent information obtained from the health record of the 
subject, the tissue and blood specimen. HIPPA compliant data security and patient confidentiality 
will be achieved through use of job-specific user name/password protection (see below). Patient 
health data will be gathered at the time the subject’s tissue is collected. Patients will be asked to 
consent separately (by means of an optional initialing box) to be contacted and/or for his/her clinical 
record to be accessed by study personnel to collect prospective data related to his primary disease 
(that would typically include outcome measures [recurrence, response to therapy]) in order to 
establish the correlation with the laboratory efficacy data. The reason prospective data is needed is 
two-fold: 
1. We do not know whether engraftment success will be related to tumor features known at 
baseline (such as site of origin, histology characteristics) or whether they would relate to 
longitudinal features, such as local aggressiveness, metastasis frequency and location, etc. 
If the latter would be the case and we had the information to establish the correlation, we 
would likely gain a relevant insight in the mechanics of xenograft models and the biology of 
xenografts. 
2. A secondary/exploratory objective is whether these humanized xenografts are predictive of 
patient response to drugs. If the latter would be the case and we had the information to 
establish the correlation, we would likely gain a relevant insight in the applicability of xenograft 
models and their potential role in individualizing therapy.  
 
Records for this study will be maintained in password-protected computers and in locked cabinets in 
the Cancer Clinical Trials Office (CCTO) of the Anschutz Cancer Center or Dr. Antonio Jimeno’s 
research laboratory. Electronic data will be kept in the standard CCTO shared drive and will be 
backed up with the frequency dictated by CCTO procedures. Each specimen will be given a study 
generated specimen number.   
 
 
 
 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 18 of 27 
USE AND PROTECTION OF HEALTH INFORMATION 
 
This project will require the use of protected health information for research purposes. A HIPPA 
authorization form will be provided to the subject at the time of consent. This authorization will 
designate the specific health information that will be required to be released.  
 
As this project requires the use of protected health information for research purposes, a signed and 
dated authorization will be collected by the qualified study staff at the time the subject is consented. 
The protected health information that will be collected and with whom it will be shared is detailed in 
the Authorization to Release Medical Information form. 
 
Clinical information regarding study subjects will not be stored within the laboratory.  Rather, the 
password-protected clinical trial management system will be used for storage of clinical information 
(see below).  Samples located in the lab will be labeled with HM indicating humanized mice, the 
tissue type and number only (e.g., the first HNSCC patient is “HM-HNSCC-001”). 
 
CONFIDENTIALITY 
 
All data and study records including hard copies and computer files will be considered confidential 
and disclosure to third parties other than those listed on the HIPAA Authorization form is prohibited. 
Subjects will be assigned a tissue collection number (specimen number).  The utmost precautions 
will be taken to ensure that PHI is not compromised. Files on the computer are password protected 
and security is maintained by firewalls. Files containing patient data will be stored in a locked office.   
 
DATA SAFETY AND MONITORING 
 
The protocol will be approved and reviewed by the Cancer Center scientific review committee 
(PRMS).  
 
The Principal Investigator will be responsible for monitoring the safety and efficacy of the trial, 
executing the DSM plan, and complying with all reporting requirements to local and federal 
authorities. This will be accomplished under the oversight of the Data & Safety Monitoring 
Committee (DSMC) of the University of Colorado Cancer Center (UCCC).  The DSMC is 
responsible for monitoring data quality and patient safety for all clinical studies at UCCC.   A 
summary of the DSMC activities follows: 
 
• 
Conduct of internal audits 
• 
Ongoing review of all reportable adverse events and all serious/unanticipated adverse events  
• 
Supervises internal DSM boards and/or performs as an internal DSMB 
• 
Has the authority to close and/or suspend trials for safety or trial conduct issues and may 
submit recommendations for corrective actions to the Associate Directors Executive 
Committee 
• 
Performs routine internal monitoring of both investigator-initiated and cooperative group 
clinical trials 
 
The PI will provide a DSM report to the UCCC DSMC on a six month basis. DSM reports will contain 
data from all participating sites. The DSM report will include summaries of minutes taken at monthly 
meetings, the participants’ demographic characteristics, expected versus actual recruitment rates, 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 19 of 27 
treatment retention rates, any quality assurance or regulatory issues (including a summary of any 
protocol deviations), summary of AEs and SAEs, summary of dose modifications, and any actions 
or changes with respect to the protocol. The DSM report to the DSMC will also include, if applicable, 
the results of any efficacy data analysis conducted. Results from these reviews will be provided to 
all participating investigators to submit to their IRBs at the time of continuing review. 
 
ADVERSE EVENT REPORTING 
 
This study is an interventional, but not therapeutic, study. Due to the use of filgrastim, we will 
conduct clinical assessments on subjects two times following the administration of filgrastim. The 
PI will follow the procedures above for reporting AEs and SAEs,if any.     
 
Definitions of Adverse Event (AE)  
 
According to the International Conference on Harmonisation (ICH) guidelines (Federal 
Register. 1997;62(90):25691-25709) and 21 CFR 312.32, IND Safety Reports, and ICH E2A, 
Definitions and Standards for Expedited Reporting, an adverse event is defined as follows:  
 
An adverse event is any untoward medical occurrence in a patient or clinical investigational 
subject administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment.  An adverse event can therefore be any unfavourable 
and unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporally associated with the use of a medicinal product, whether or not considered 
related to the medicinal product. 
 
Definitions of a Serious Adverse Event (SAE)  
 
An adverse event should be classified as a serious adverse event if it meets one of the 
following criteria: 
 
Fatal: 
Adverse event resulted in death 
 
Life 
threatening: 
The adverse events placed the patient at immediate risk of 
death. This classification did not apply to an adverse event that 
hypothetically might cause death if it were more severe. 
 
Hospitalization: 
The AE required or prolonged an existing inpatient 
hospitalization. Hospitalizations for elective medical or surgical 
procedures or treatments planned before the signing of 
informed consent in the study or routine check-ups are not 
serious adverse events by this criterion. Admission to a 
palliative unit or hospice care facility is not considered to be a 
hospitalization.  Hospitalizations or prolonged hospitalizations 
for scheduled therapy of the underlying cancer or study target 
disease need not be captured as SAEs. 
 
Disabling/ 
incapacitating: 
Resulted in a substantial and permanent disruption of the 
patient’s ability to carry out activities of daily living. 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 20 of 27 
Congenital 
anomaly or 
birth defect: 
An adverse outcome in a child or fetus of a patient exposed to 
the molecule or study treatment regimen before conception or 
during pregnancy. 
 
Medically 
significant: 
The adverse event did not meet any of the above criteria, but 
could have jeopardized the patient and might have required 
medical or surgical intervention to prevent one of the outcomes 
listed above. 
 
 
All AEs and SAEs, if any, will be reported to the COMIRB at the University of Colorado Anschutz 
Medical Campus according to institutional guidelines, and to the UCCC DSMC as stated above. 
 
DATA PROTECTION/FIREWALLS 
 
Clinical Information on study subjects will be entered in a clinical trial management system which is 
a remote, firewalled system used for clinical trials at the University of Colorado. CRA’s are given 
access to specific protocol data only after special training, and each CRA has a specific login and 
password. Clinical data on study subjects will be maintained on this system. 
 
FUNDING AND INTELLECTUAL PROPERTY 
 
The University of Colorado School of Medicine is sponsoring this tissue collection and lab work via 
divisional and grant funds. The funding supports patient expenses (G-CSF, labs, exams), the blood 
and tissue collection, and all preclinical lab work. We anticipate that preliminary data generated from 
this project will lead to multiple other grant opportunities. It is possible future funding for the 
conduction of experiments and tests will involve collaborations with other academic medical centers, 
universities, or pharmaceutical/laboratory companies. We anticipate such collaborations will occur 
when the University of Colorado does not have the necessary expertise for specific assays, when 
large numbers of xenografts are needed (and therefore pooled from multiple institutions), or when 
costs would be prohibitive. 
 
The Cancer Center Clinical Trials Core Grant will also be sponsoring part of this protocol.  This grant 
will be paying for part of regulatory and coordination of this protocol.  
 
There are no anticipated costs to the patient for participation in this research. Patients will not be 
paid for their participation in this study. 
 
Intellectual property issues will be managed according to the University of Colorado Denver policies 
as implemented by the Technology Transfer office. 
 
 
 
 
 
 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 21 of 27 
SPECIAL POPULATIONS 
 
No special populations are targeted for accrual to this study. 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 22 of 27 
References 
 
1. 
Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., 
Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. 2010. Improved survival with 
ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723. 
2. 
Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, 
P., Joseph, R.W., Weber, J.S., et al. 2013. Safety and tumor responses with lambrolizumab 
(anti-PD-1) in melanoma. N Engl J Med 369:134-144. 
3. 
Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., Hamid, O., 
Schuchter, L., Cebon, J., Ibrahim, N., et al. 2012. Combined BRAF and MEK inhibition in 
melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703. 
4. 
Weber, J.S., Kudchadkar, R.R., Yu, B., Gallenstein, D., Horak, C.E., Inzunza, H.D., Zhao, X., 
Martinez, A.J., Wang, W., Gibney, G., et al. 2013. Safety, efficacy, and biomarkers of 
nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31:4311-
4318. 
5. 
Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, 
N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. 2013. Nivolumab plus ipilimumab in 
advanced melanoma. N Engl J Med 369:122-133. 
6. 
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. 2007. Cancer statistics, 
2007. CA Cancer J Clin 57:43-66. 
7. 
Chaturvedi, A.K., Engels, E.A., Anderson, W.F., and Gillison, M.L. 2008. Incidence trends for 
human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United 
States. J Clin Oncol 26:612-619. 
8. 
Bonner, J.A., Harari, P.M., Giralt, J., Azarnia, N., Shin, D.M., Cohen, R.B., Jones, C.U., Sur, 
R., Raben, D., Jassem, J., et al. 2006. Radiotherapy plus cetuximab for squamous-cell 
carcinoma of the head and neck. N Engl J Med 354:567-578. 
9. 
Jimeno, A., Kulesza, P., Rubio-Viqueira, B., Zhang, X., Maitra, A., and Hidalgo, M. 
Individualizing therapy using direct xenografting of pancreas cancers: a multi-modality 
approach. 2006 AACR International Conference on Molecular Diagnostics in Cancer 
Therapeutic Development. Abst #97. 
10. 
Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., 
Shi, C., Danenberg, K., Danenberg, P.V., Kuramochi, H., et al. 2006. An in vivo platform for 
translational drug development in pancreatic cancer. Clin Cancer Res 12:4652-4661. 
11. 
Hidalgo, M., Amador, M.L., Jimeno, A., Mezzadra, H., Patel, P., Chan, A., Nielsen, M.E., 
Maitra, A., and Altiok, S. 2006. Assessment of gefitinib- and CI-1040-mediated changes in 
epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial 
fine needle aspiration. Mol Cancer Ther 5:1895-1903. 
12. 
Jimeno, A., Hallur, G., Chan, A., Zhang, X., Cusatis, G., Chan, F., Shah, P., Chen, R., Hamel, 
E., Garrett-Mayer, E., et al. 2007. Development of two novel benzoylphenylurea sulfur 
analogues and evidence that the microtubule-associated protein tau is predictive of their 
activity in pancreatic cancer. Mol Cancer Ther. 
13. 
Jimeno, A., Amador, M.L., Kulesza, P., Wang, X., Rubio-Viqueira, B., Zhang, X., Chan, A., 
Wheelhouse, J., Kuramochi, H., Tanaka, K., et al. 2006. Assessment of celecoxib 
pharmacodynamics in pancreatic cancer. Mol Cancer Ther 5:3240-3247. 
14. 
Jimeno, A., Rubio-Viqueira, B., Amador, M.L., Grunwald, V., Maitra, A., Iacobuzio-Donahue, 
C., and Hidalgo, M. 2007. Dual mitogen-activated protein kinase and epidermal growth factor 
receptor inhibition in biliary and pancreatic cancer. Mol Cancer Ther 6:1079-1088. 
15. 
Jimeno A, Wheelhouse J, Chan F, Solomon A, Maitra A, Hidalgo M. Rational identification of 
combination partners with gemcitabine in pancreatic cancer: polo-like kinase 1. 99th 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 23 of 27 
American Association for Cancer Research (AACR) Annual Meeting, oral presentation, abstr 
1597, April 2008. 
16. 
Jimeno, A., Tan, A.C., Coffa, J., Rajeshkumar, N.V., Kulesza, P., Rubio-Viqueira, B., 
Wheelhouse, J., Diosdado, B., Messersmith, W.A., Iacobuzio-Donahue, C., et al. 2008. 
Coordinated epidermal growth factor receptor pathway gene overexpression predicts 
epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 
68:2841-2849. 
 
 
 
 
 
 
 
 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 24 of 27 
Appendix A 
 
Blood/Tissue Collection, Handling, and Processing Instructions 
 
Tumor samples will be obtained from consenting patients at the University of Colorado Hospital in 
accordance with protocols approved by the Colorado Multiple Institutional Review Board 
(COMIRB).  
 
Whole Blood for Genomic Testing  
 
Collection:  
10 mL of blood in one (1) 10mL sodium heparin green-top tube.  
Handling:  
Deliver samples to Jimeno Lab immediately after collection. 
Processing:  Put at 4C. Invert and mix. Aliquot as is in 3 cryovials.  
 
Whole Blood for SC Harvesting 
 
Collection:  
50 mL of blood will be collected in ten (10) 10mL sodium heparin green-top tubes.  
Handling:  
Deliver samples to Jimeno Lab immediately after collection. 
Processing:  Put at 4C. Invert and mix. Blood samples will be processed by the Jimeno lab 
following the established protocol. 
 
Blood Sample for Circulating B and T Cell Distribution 
 
Collection:  
10 mL of blood in one (1) 10mL sodium heparin green-top tube.  
Handling:  
Deliver samples to Jimeno Lab immediately after collection. 
Processing:  Put at 4C. Invert and mix. Blood samples will be processed by the Jimeno lab 
following the established protocol. 
 
Optional Sequential Blood Samples  
 
Collection:  
10 mL of blood in one (1) 10 mL sodium heparin green-top tube.  
Handling:  
Deliver samples to Jimeno Lab immediately after collection. 
Processing:  Put at 4C. Invert and mix. Blood samples will be processed by the Jimeno lab 
following the established protocol. 
 
Blood for CBC and CMP 
 
Per clinical laboratory standards. 
 
Tumor and normal tissue from biopsy or surgical resection specimens 
 
Collection:  
Excisional or core biopsy of the most accessible lesion in the opinion of the ENT or 
Cutaneous Cancer clinical providers. The minimum size required is 3 x 1 mm. 
Processing:   
 
• 
Tissue samples collected will be implanted in mice in the Jimeno Lab following the 
established protocol. Tissue samples will be stored frozen and paraffin-embedded, and kept 
alive in the mouse live bank and as cell lines indefinitely. 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 25 of 27 
• 
 For research-specific samples, after the tumor is resected samples will be taken for 
immediate processing, and the specimen will be delivered from the clinical or surgical suite 
to the study team. 
• 
For samples taken as part of standard of care surgical or biopsy management the 
Pathology House Staff responsible for the specimen will guide and instruct the trial 
personnel in the dissection to the specimen, such that the tissue collection process in no 
way compromises pathologic diagnostic practice. 
• 
The trial technical personnel will be paged ahead of time, and will be present in the clinic or 
grossing area. 
• 
Fragments of tumor tissue and grossly normal tissue will be collected, each not smaller 
than 0.2 cm in the smallest dimension. 
o Tumor tissue. As much excess tumor tissue as possible will be collected, in the 
following order of priority: 
A. 1 fragment (ideally 0.5 to 1 gram, or a piece 0.7-1.0 cm in diameter) collected in 
warm RPMI medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. 
B. 1 fragment placed in a cryovial and frozen in liquid N2. 
C. 1 fragment placed in a vial containing PBS buffered formalin (only one). 
o Normal tissue. As much excess normal tissue as possible will be collected, in the 
following order of priority: 
A. 1 fragment placed in a cryovial and frozen in liquid N2. 
B. 1 fragment placed in a vial containing PBS buffered formalin (only one). 
• 
Both for tumor and normal tissue as many vials of N2-preserved tissue will be collected. 
 
 
Tissue Sample Implantation in Mice 
 
Tumor tissues will be implanted in mice following the procedures listed in the protocol Generation 
of a cancer direct xenograft colony with primary and metastatic tumors that has been 
approved by the University of Colorado Institutional Animal Care and Use Committee. Animals are 
maintained under the American Association of Laboratory Animal Care guidelines. Briefly, after 
washing several times in media, tumors will be cut into pieces measuring approximately 3-4 mm in 
diameter while submerged in antibiotic containing medium, dipped in matrigel to explant into mice. 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 26 of 27 
 
Screening 
G-CSF mobilization and HSC Harvest  
(Does not need to be completed prior to Biopsy) 
Primary Biopsy & 
Implantation 
Additional/Optional 
Tumor Biopsies & Blood Collection 
Cycle 1 
≥ Cycle 2 
Assessment 
Day 
Any time between consent 
and next anti-cancer 
treatment  
Day of anti-cancer treatment 
-14 to -1 
1 
(Baseline) 
2 
3 
4 
5 
6 
(+/- 1 day) 
7 
(+/- 1 day) 
35 to 42 
Prior to 
treatment start 
21 
(+/- 2 days) 
21 
(+/- 2 days) 
Informed Consent 1 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Medical History 2 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Physical Exam 3 
X 
 
 
 
 
 
 
X(+ 2 days) 
 
 
 
 
 
Vital Signs 4 
X 
 
 
 
 
 
 
 
 
 
 
 
 
O2 Saturation 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Prior/Concomitant 
Medication 5 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline Condition 
Assessment  
X 
X18 
 
 
 
 
 
 
 
 
 
 
 
ECOG 6 
X 
 
 
 
 
 
 
 
 
 
 
 
 
CMP (Chemistry) 7 
X 
 
 
 
 
 
 
X(+ 2 days) 
 
 
 
 
 
CBC 8 
X 
 
 
 
 
 
 
X(+ 2 days) 
 
 
 
 
 
Tumor Measurements 9 
X 
 
 
 
 
 
 
 
 
X 
X 
Whole Blood for 
Genomic Testing 10 
X 
 
 
 
 
 
 
 
 
 
 
 
 
G-CSF administration 11 
 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
Blood sample for Circ. 
B and T cell distrib. 
 
 
 
 
 
 
 
 
 
X 
 
 
 
HSC Harvesting 12 
 
 
 
 
 
 
X 
X 
 
 
 
 
 
Primary tumor biopsy 13 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Optional Consent  
for Subsequent 
Blood/Biopsy14 
 
X 
 
 
Optional Sequential 
Tumor Biopsy 15 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
Optional Sequential 
Blood 16 
 
 
 
 
 
 
 
 
 
 
X 
X 
X 
Adverse Events 17 
 
X 
 
 
 
 
 
X(+ 2 days) 
X17 
 
 
 
 
Optional Tissue 
Collection from SOC 19 
 
X 
Optional Research 
Tumor Biopsy 
 
X 


COMIRB 14-0842 
Version Date: June 1, 2017 
Amendment 5 
Full Protocol 
 
CONFIDENTIAL 
 
 Page 27 of 27 
 
1. 
Informed Consent will be obtained for study participation. 
2. 
Medical History: This will be performed as part of screening evaluation for study participation within 14 days of study initiation.   
3. 
Physical exam:  This will be performed as part of screening evaluation for study participation within 14 days of study initiation.  
4. 
Vital Signs to include: BP (systolic and diastolic), pulse, respiration rate, and body temperature. To be collected within 14 days of study initiation. 
5. 
Prior/Concomitant Medications:  Medications and vitamins/supplements that the patient is taking will be reviewed at each time point indicated. 
6. 
ECOG Performance Status:  Must be 0, 1, or 2 at time of study enrollment.  
7. 
Chemistry Panel (CMP) includes: Sodium (Na), Potassium (K), Chloride (Cl), Blood Urea Nitrogen (BUN), Creatinine (Cr), Alkaline Phosphatase 
(Alk Phos), Aspartate Aminotransferase (AST),  Alanine Aminotransferase (ALT), Total Protein (TP) and Albumin (Alb). 
8. 
Complete Blood Count (CBC) includes: Total white blood cells (WBC), Hemoglobin (Hgb), Platelet Count (Plt), Absolute Neutrophil Count (ANC), 
volume parameters, formula.  
9. 
Tumor Response Measurements:  
• For screening, measureable disease will be determined by standard clinical practice per the investigator. 
• Prior to biopsies, patients will have tumor measurements per standard clinical practice as determined by the provider performing the biopsy. 
• For patients who initiation subsequent treatment regimens, tumor measurements will be conducted as per standard clinical practice for each 
patient’s disease, as determined by their standard of care clinical research team. 
• Response data will be collected from radiological imaging or clinical assessments if determined to be relevant by the Principal Investigator. Data 
collected will be evaluated using the Response Criteria in Solid Tumors (RECIST) version 1.1, if applicable and relevant.  
10. Whole Blood Sample for Genomic Testing: 10 mL prior to Day 1 G-CSF administration. 
11. G-CSF Administration: Patients will receive 10 µg/kg/day G-CSF subcutaneously in a 4-day mobilization schedule  
12. HSC Harvest: Conducted on days 6 and 7 until a sufficient number of HSC are collected (at least 2 x 106) by means of peripheral blood draw of 100 
mL per day. 
13. Excisional or core biopsy of most accessible lesion. Requires minimum size of 3 mm x 1 mm. Implanted once humanized mice are ready to be 
implanted (typically 4-8 weeks post HSC infusion into mice). 
14. Optional Subsequent Blood/Biospy Consent: The patient must sign the Consent for Optional Subsequent Tumor Biopsies and Blood Collection (if 
relevant to the main study) prior to any additional samples being collected not stipulated in first consent. Can be collected at other points during study 
other than screening.  Must be performed within 4 weeks of the initiation of Cycle 1 Day 1 of study related treatments. 
15. Optional Sequential Tumor Biopsies: Samples to be collected once patient starts each new anti-cancer therapy deemed to be of relevance for 
humanized model. Samples should be collected sequentially prior to C1D1 of therapy, then once more at Day 21 of treatment (+/- 2 days). If no 
intervening therapy had occurred from the time of the Primary Tumor Biopsy, the pre-treatment biopsy may be waived by the Principal Investigator. 
Subsequent biopsies can include safely accessible skin lesions, nodes, liver lesions, etc.  
16. Optional Sequential Blood Samples: Samples to be collected once patient starts each new anti-cancer therapy deemed to be of relevance for 
humanized model. Samples should be collected sequentially prior to C1D1 of therapy, then every 21 days thereafter (+/- 2 days). This can occur 
before or after the Primary Tumor Biopsy. If no intervening therapy had occurred from the time of the Primary Tumor Biopsy, the pre-treatment blood 
sample may be waived by the Principal Investigator. 
17. Adverse Event Assessments: Adverse events will be assessed in person or over the phone by the PI or sub-investigator. Follow-up AE 
assessment will occur 30 days post-harvest +/- 2 days (days 35 to 42). 
18. Baseline Condition Assessment: Repeat at Baseline/Day 1 if not done in prior 14 days 
19. Optional Tissue Collection from SOC: If the patient consents to optional tissue collection (Main Consent Form, “Optional Procedure 2 - Optional 
Future Tissue Biopsies – Standard of Care”), we will collect excess tissue from any additional scheduled biopsies or resections, as part of his/her 
regular clinical care for HNSCC or melanoma. 
20. Optional Research Tumor Biopsy: If the patient signs the Optional Research Tumor Biopsy (Non-Standard of Care) Consent Form the patient will 
have a core biopsy of tumor areas, with radiologic guidance with ultrasound if required. 


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 1 of 11
Initials______
Principal Investigator:
Antonio Jimeno, MD
COMIRB No:
14-0842
Version Date:
 June 1, 2017
Study Title:
Pilot Study of Tissue and Hematopoietic/Mesenchymal Stem Cell Collection for 
Humanized Xenograft Studies in Melanoma and Squamous Head and Neck 
Cancer
You are being asked to be in a research study.  This form provides you with information about 
the study. A member of the research team will describe this study to you and answer all of your 
questions. Please read the information below and ask questions about anything you don’t 
understand before deciding whether or not to take part. 
Why is this study being done?
This study plans to learn more about melanoma and head and neck squamous cell cancer 
(HNSCC). 
You are being asked to be in this research study because you were diagnosed as having 
melanoma or HNSCC.  We are asking you to agree to let us collect your blood and tumor tissue 
samples so we can study how your cancer may grow if we put it into mice. This is called 
xenograft.  By growing the tumor in the mouse, rather than in a petrie dish, we will be able to 
learn from a larger and more varied number of samples more quickly. We also refer to this as 
humanized models. Your samples will be tested in the humanized models to determine 
individual characteristics of the cancer cells. We will also test anti-cancer drugs. We hope to 
learn what predicts that a patient will benefit from a treatment and to discover better and more 
individualized treatments for these cancers.
Other people in this study
Up to 40 people from your area will participate in the study. 
What happens if I join this study?
If you join the study, you will be asked to read and sign this consent form. This study has both 
study related procedures and optional research procedures which will be listed here. Optional 
parts of this study are not required. You will be given the choice at the end of this section to take 
part in the optional procedures if you want to.
Before the Study (Screening) Procedures:

Review your medical history

A physical exam (check height, weight, vital signs, O2 saturation, etc.)

Review your current medications
COMIRB
APPROVED
For Use
14-Jun-2017
13-Jun-2018


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 2 of 11
Initials______

Laboratory blood tests including complete blood count and comprehensive metabolic 
panel (check liver and kidney functions, etc.) 

We will draw about 2 teaspoons of blood for germline DNA testing. Germline testing 
looks at a line or sequence of germ cells that have genetic material that may be 
passed to a child or may be present in your family.   The results of this testing will not 
be placed in your medical record, given to your doctor or given to you.
During the Study Procedures:
Blood Collections and Blood Booster

On 4 consecutive days  you will be given, or directed how to give yourself, a 
blood booster called filgrastim so we may obtain peripheral 
hematopoietic/mesenchymal stems cells (HSC). This use of filgrastim is also 
called granulocyte colony-stimulating (G-CSF). Filgrastim is being used for a 
purpose that is not currently approved by the FDA. 

You will have one day without injections and blood draws, and then we will 
collect your blood on two consecutive days, or as soon as your HSC level is 
sufficient. We will draw a little more than 6 tablespoons of blood each day to 
collect HSC blood samples. 
-
We will also draw 2 teaspoons of blood for standard laboratory tests 
(including 1 teaspoon each for complete blood count, and comprehensive 
metabolic panel).  
-
We will also ask you questions about your health, how you are feeling 
and if you are having any side effects.
In the rare event we do not get enough cells we may repeat the above process a 
few weeks after the first round.
Primary Tumor Biopsy and Blood Collection. These procedures can be done before the 
blood collection, at the same time as the HSC blood collection or they can be done later.  

You will have a tumor biopsy. 

We will draw about 2 teaspoons of blood to determine circulating white blood cell 
distribution. If this procedure is done at the same time as the HSC collection then 
this will not be a separate procedure.

If you have previously participated in a xerograph research study collecting tumor 
tissue with Dr. Jimeno as the principal investigator, we may be able to waive the 
tumor biopsy portion of the study. 
Follow-up. About 30 days after your last HSC blood collection

We will contact you by phone or in person to ask you questions about your 
health, how you are feeling, and if you are having any side effects.  


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 3 of 11
Initials______
Main Study Samples Use:
We will process and use these blood and tumor samples to be implanted into mice and 
generate cell lines. These cell lines may potentially live forever. We will compare blood and 
tumor protein, immune and genetic profiles. We will explore various laboratory processes to 
improve our methods. We will use some of these blood and tumor samples for experiments and 
comparisons with other patient’s samples, since in this project we will acquire samples from 40 
patients. We will also keep samples frozen in case we need to repeat the experiments. 
We may ask if you would be willing to provide additional blood and tumor tissue samples. Any 
request for additional samples is optional. You can choose to participate or not. This will be 
discussed further in the Optional Study Procedures section below. 
Optional Study Procedures:
Optional parts of this study are voluntary and are not required. You can still participate in the 
main study if you choose not to take part in the optional study procedures. 
Each optional part of the study will be described here. No matter what you decide to do about 
these optional parts of the study, you may still take part in the main study.
Optional Procedure 1
Possible Subsequent Tumor Biopsies and Blood Collection 
(if relevant to the main study)
 
We may ask you if you would be willing to provide additional Research Tumor Biopsies 
and Blood Draws. If your cancer treatment changes, we might request the following 
additional research samples:
o
Blood Samples – every 21 days (for the duration of anti-cancer therapy)
o
Tumor Tissue Biopsies 

Before starting any therapy (at the discretion of the study doctor)

21 days after starting any therapy
You have the option of whether or not you want to provide these additional samples. If 
we request these additional research samples, you will be given a separate optional 
consent to read and consider at that time.
Optional Procedure 2
Optional Future Tissue Biopsies – Standard of Care
It is possible that you may have additional tissue biopsies scheduled as part of your 
standard medical care. If so, we would like to ask if you would be willing to donate 
excess tissue from these future procedures. 


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 4 of 11
Initials______
We would also like to keep a sample of this tissue frozen (cryopreserved) for future 
research called “banking”. Future banking is another optional procedure and you will be 
asked separately below if you wish to take part in that optional procedure.
Please read the statement below. Check “Yes” or “No”, and initial to indicate your 
choice. If you have any questions, please talk to your doctor or nurse. 
Would you be willing to donate excess tissue obtained from any subsequent 
(additional) biopsies or surgeries as part of your regular clinical care for 
melanoma or HNSCC?
   Yes
   No
_________Initials
Optional Procedure 3
Optional Future Tissue Biopsies – For Research (Non-Standard of Care)
We may ask if you are willing to provide an additional tumor biopsy.  If you are not 
scheduled for a tissue biopsy as part of your standard medical care, you may be given a 
separate optional consent to read and consider at that time.
Optional Procedure 4
Optional Consent for Data and Specimen Banking for Future Research
Dr. Antonio Jimeno would like to keep some of the data, blood and tissue that is taken 
during the study but is not used for other tests. If you agree, the data and samples will 
be kept and may be used in future research to learn more about melanoma and head 
and neck squamous cell cancer (HNSCC). The research that is done with your data and 
samples is not designed to specifically help you. It might help people who have 
melanoma and HNSCC and other diseases in the future. Reports about research done 
with your data and samples will not be given to you or your doctor. These reports will not 
be put in your health records. The research using your data and samples will not affect 
your care.
The choice to let Dr. Antonio Jimeno keep the data and samples for future research is up 
to you. No matter what you decide to do, it will not affect the care that you will receive as 
part of the study. If you decide now that your data and samples can be kept for research, 
you can change your mind at any time and contact your study doctor to let him or her 
know that you do not want Dr. Antonio Jimeno to use your data and samples any longer, 
and they will no longer be used for research. Otherwise, they may be kept until they are 
used up, or until Dr. Antonio Jimeno decides to destroy them. 
When your data and samples are given to other researchers in the future, Dr. Antonio 
Jimeno will not give them your name, address, phone number or any other information 
that will let the researchers know who you are. 


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 5 of 11
Initials______
Sometimes data and samples are used for genetic research (about diseases that are 
passed on in families). Even if your data and samples are used for this kind of research, 
the results will not be told to you and will not be put in your health records. Your data 
and samples will only be used for research and will not be sold. The research done with 
your data and samples may help to develop new products in the future, but there is no 
plan for you to be paid.
The possible benefits of research from your data and samples include learning more 
about what causes melanoma and HNSCC and other diseases, how to prevent them 
and how to treat them. The greatest risk to you is the release of your private information. 
Dr. Antonio Jimeno will protect your records so that your name, address and phone 
number will be kept private. The chance that this information will be given to someone 
else is very small. There will be no cost to you for any data or sample collection and 
storage by Dr. Antonio Jimeno.
Please read each sentence below and think about your choice. After reading each 
sentence, circle “yes” or “no.” If you have questions, please talk to your doctor or nurse. 
Remember, no matter what you decide to do about the storage and future use of your 
data and samples, you may still take part in the study.
I give my permission for my data and tissue to be stored in a central tissue bank at the 
University of Colorado for future use by the study investigators:
1.
I give my permissions for my data, blood and tissue samples to be 
kept by Dr. Antonio Jimeno for use in future research to learn more 
about how to prevent, detect, or treat melanoma and HNSCC.
   Yes
   No
_________Initials
2.
I give my permissions for my data, blood and tissue samples to be 
used for research about other health problems (for example: causes 
of heart disease, osteoporosis, diabetes).
   Yes
   No
_________Initials
3.
I give my permission for my study doctor (or someone he or she 
chooses) to contact me in the future to ask me to take part in more 
research.
   Yes
   No
_________Initials
If you decide to withdraw your consent for the optional parts, you can continue to take part in the 
main study, unless you withdraw your consent for the main study as well.  
At the end of this consent form, you will also be asked to allow information collected from your 
optional specimen donations to be used. You need to agree to have information from these 
optional procedures to be used, or you cannot take part in these optional study procedures.


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 6 of 11
Initials______
What are the possible discomforts or risks?
Discomforts you may experience while in this study include:
Risks of taking Filgrastim (G-CSF):
The risks associated with receiving filgrastim for boosting cell production for collection are 
mild-to-moderate muscle and/or bone pain and mild headache.
Other rare but serious potential risks of filgrastim include:

Allergic reaction: it has been reported in less than 1 in 4000 administrations
o
skin reaction (rash‚ itching‚ facial blisters)
o
wheezing or labored breathing
o
Low blood pressure (hypotension)
o
Rapid heart beating (tachycardia). 
These symptoms generally go away after taking antihistamines‚ steroids‚ 
bronchodilators‚ and/or epinephrine. 

Splenic rupture has been reported following the administration of filgrastim. If you 
have pain in your left side of your abdomen you should contact your doctor.

Acute Respiratory Distress Syndrome. If you develop fever, or labored breathing you 
should contact your doctor. 
Filgrastim has not been studied in pregnant women so if you become pregnant, the 
particular treatment or procedures involved in the study may involve risks to the embryo or 
fetus which are currently unclear. While participating in this research study, you should 
not become pregnant, father a baby, or nurse a baby. Let your research doctor know 
immediately if you become pregnant or find out that you are going to be the father of 
a child.  Talk to your doctor about ways to prevent pregnancy. 
Risks of Having Blood Taken
At different points during this study we will need to get about 10 tablespoons of blood from 
you. We will get blood by putting a needle into one of your veins and letting the blood flow 
into a glass tube.  You may feel some pain when the needle goes into your vein.  A day or 
two later, you may have a small bruise where the needle went under the skin. 
Risk of Having a Tumor Biopsy
In this study we will need to have one or more small sample(s) of your tumor.  This 
procedure is called a “biopsy.”  Before we take the sample(s), we will give you some 
medicine to numb the area.  We will then make a small cut in your skin and take the 
sample(s) by pressing a hollow needle into your tumor tissue. When we take the needle out, 
it will remove a small circle of your tumor tissue called a “plug.”   
There are some risks to taking a sample of tumor tissue in this way.  There is a small 
chance that taking a sample of tumor tissue this way could cause an infection where the 
needles go in. You could also have an allergic reaction to the numbing medicine.  But this is 
rare.  After your skin heals up, you may have a small scar where we took the sample. 


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 7 of 11
Initials______
Risk of Loss of Confidentiality
There is a risk that people outside of the research team will see your research information.  
We will do all that we can to protect your information, but it cannot be guaranteed.
Other possible risks include:
If you become pregnant, the particular treatment or procedures involved in the study may 
involve risks to the embryo or fetus which are currently unclear. 
The study may include risks that are unknown at this time. 
What are the possible benefits of the study?
This study is designed for the researcher to learn more about melanoma and HNSCC.  
This study is not designed to treat any illness or to improve your health.  Also, there may be 
risks, as discussed in the section describing the discomforts or risks.
.
Who is paying for this study? 
This research is being sponsored by the University of Colorado the National Institutes of Health 
and the National Cancer Institute.
Financial Disclosure 
Dr. Gonzalez, one of the study doctors involved with this clinical trial, is on the advisory 
board for the study drug manufacturer in the past 12 months. Please feel free to ask any 
further questions you might have about this matter.
Will I be paid for being in the study?  
You will not be paid to be in the study. 
You may be eligible for travel, meal and/or lodging reimbursement.  Talk to the study team for 
more information.
Will I have to pay for anything?
It will not cost you anything to be in the study. 
The University of Colorado will pay for all study procedures as well as filgrastim and any 
medication used for the research tumor biopsy you will get in this study. You will not have to pay 
for any medical care that is part of this study. 


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 8 of 11
Initials______
Is my participation voluntary?
You do not have to be in this study if you do not want to be.  Even if you decide to be in this 
study, you can change your mind and stop at any time.  If we learn new information that might 
make you want to leave this study, we will tell you about it. 
If you leave this study, you will not lose any of the benefits that you would normally get outside 
of this study.  Leaving this study will not affect your employment status or your reputation.  
Leaving this study will not change your ability to get government assistance.  If you leave this 
study, the only benefits that you will lose are the ones you are getting as part of this study.
Can I be removed from this study? 
You may be taken out of this study if the study doctor thinks it is not safe for you to be in the 
study.  You can be taken out of the study even if you do not want to leave the study.  
If you are taken out of this study, you will not lose any of the benefits that you would normally 
get outside of the study.  Being taken out of the study will not affect your employment status or 
your reputation.  Being taken out of the study will not change your ability to get government 
assistance.  If you are taken out of the study, the only benefits you will lose are the ones you are 
getting as part of this study.
What happens if I am injured or hurt during the study? 
If you have an injury while you are in this study, you should call Dr. Antonio Jimeno immediately. 
His phone number is 720-848-1543 or 720-848-0000 (24 hour contact number, ask for the 
medical oncology fellow on-call).
We will arrange to get you medical care if you have an injury that is caused by this research.  
However, you or your insurance company will have to pay for that care. 
Who do I call if I have questions?
The researcher carrying out this study is Dr. Antonio Jimeno. You may ask any questions you 
have now. If you have questions, concerns, or complaints later, you may call Dr. Antonio Jimeno 
at 720-848-1543. You will be given a copy of this form to keep.  
You may have questions about your rights as someone in this study. You can call Dr. Antonio 
Jimeno with questions.  You can also call the responsible Institutional Review Board (COMIRB).  
You can call them at 303-724-1055. 
Who will see my research information?
The University of Colorado Denver (UCD) and its affiliated hospital(s) have rules to protect 
information about you. Federal and state laws including the Health Insurance Portability and 
Accountability Act (HIPAA) also protect your privacy. This part of the consent form tells you 
what information about you may be collected in this study and who might see or use it.  


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 9 of 11
Initials______
The institutions involved in this study include:

University of Colorado Denver

University of Colorado Hospital
We cannot do this study without your permission to see, use and give out your information.  You 
do not have to give us this permission. If you do not, then you may not join this study.  
We will see, use and disclose your information only as described in this form and in our Notice 
of Privacy Practices; however, people outside the UCD and its affiliate hospitals may not be 
covered by this obligation.
We will do everything we can to maintain the confidentiality of your personal information but 
confidentiality cannot be guaranteed. 
The use and disclosure of your information has no time limit. You can cancel your permission to 
use and disclose your information at any time by writing to the study’s Principal Investigator (PI), 
at the name and address listed below. If you do cancel your permission to use and disclose your 
information, your part in this study will end and no further information about you will be 
collected. Your cancellation would not affect information already collected in this study.  
Antonio Jimeno, MD, PhD
University of Colorado Denver 
University of Colorado Cancer Center
P.O. Box 6511
Campus Box 8117
Aurora, Colorado 80045
Both the research records that identify you and the consent form signed by you may be looked 
at by others who have a legal right to see that information, such as:  

Federal offices such as the Food and Drug Administration (FDA) and the Office of 
Human Research Protections (OHRP) that protect research subjects like you.

People at the Colorado Multiple Institutional Review Board (COMIRB)

The study doctor and the rest of the study team.

The University of Colorado School, the entity who is paying for this research study.

Officials at the institution where the research is conducted and officials at other 
institutions involved in this study who are in charge of making sure that we follow all of 
the rules for research
We might talk about this research study at meetings.  We might also print the results of this 
research study in relevant journals.  But we will always keep the names of the research 
subjects, like you, private. 
You have the right to request access to your personal health information from the Investigator. 
Some of the research procedures involve genetic testing or the use of your genetic information.  
Your genetic information will not be released to others.  


Consent and Authorization Form 
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 10 of 11
Initials______
Information about you that will be seen, collected, used and disclosed in this 
study:

Name and Demographic Information (age, sex, ethnicity, address, phone number, etc.).

Your social security number

Portions of your previous and current Medical Records that are relevant to this study, 
including but not limited to Diagnosis(es), History and Physical, laboratory or tissue 
studies, radiology studies, procedure results

Research Visit and Research Test records

Blood and Tissue samples and the data with the samples. 

Billing or financial information
What happens to Data, Tissue, Blood and Specimens that are collected in this 
study?
Scientists at the University of Colorado Denver and the hospitals involved in this study work to 
find the causes and cures of disease.  The data, tissue, blood and specimens collected from 
you during this study are important to this study and to future research.  If you join this study:

The data, tissue, blood, or other specimens given by you to the investigators for this 
research no longer belong to you.  

Both the investigators and any sponsor of this research may study your data, tissue, 
blood, or other specimens collected from you.

If data, tissue, blood, or other specimens are in a form that identifies you, UCD or the 
hospitals involved in this study may use them for future research only with your consent 
or Institutional Review Board (IRB) approval.

Any product or idea created by the researchers working on this study will not belong to you.

There is no plan for you to receive any financial benefit from the creation, use or sale of 
such a product or idea. 
HIPAA Authorization for Optional Additional Study Procedures 
In this form, you were given the option to agree to additional, optional research procedures.  
You must also give us your permission, under HIPAA rules, to use and disclose the information 
collected from these optional procedures, as described above.  
Some of these optional procedures may involve genetic testing or the use of your genetic 
information.  Your genetic information will not be released to others.
If you decline to give us permission to use and disclose your information, you cannot take part in 
these optional procedures, but you can still participate in the main study.  Please initial next to 
your choice:
_____ I give permission for my information, from the optional procedures I have agreed to 
above, to be used and disclosed as described in this section.
_____ I do not give permission for my information for any optional procedures to be used 
and disclosed; I understand that I will not participate in any optional procedures.


C o n s e nt a n d A ut h o ri z ati o n F o r m 
C o m bi ne d Bi o me dical C o nse nt a n d C o m p o u n d HI P A A a ut h orizati o n
C F- 1 5 1. C, Effecti ve 7- 1 9- 1 3
P a g e 1 1 of 1 1
I niti al s _ _ _ _ _ _
A gr e e m e nt t o b e i n t hi s st u d y a n d u s e m y  d at a
I h a v e r e a d t hi s p a p er a b o ut t h e st u d y or it w a s r e a d t o m e.  I u n d er st a n d t h e p o s si bl e ri s k s a n d 
b e n efit s of t hi s st u d y.  I u n d er st a n d a n d a ut h ori z e t h e a c c e s s, u s e a n d di s cl o s ur e of 
m y 
i nf or m ati o n a s st at e d i n t hi s f or m.  I k n o w t h at b ei n g i n t hi s st u d y i s v ol u nt ar y.  I c h o o s e t o b e i n 
t hi s st u d y: I will g et a si g n e d a n d d at e d c o p y of t hi s c o n s e nt f or m.
Si g n at ur e: 
D at e: 
Pri nt N a m e: 
C o n s e nt f or m e x pl ai n e d b y: 
D at e: 
Pri nt N a m e: 
I n v e sti g at or: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
D at e: 
I n v e sti g at or m u st si g n wit hi n 3 0 d a y s
If a p pli c a bl e, t h e si g n at ur e li n e f or wit n e s s b el o w i s r e q uir e d f or c o n s e nt of n o n-r e a di n g 
s u bj e ct s, d e ci si o n all y c h all e n g e d a d ult s, or c o n s e nt u si n g a s h ort  f or m.
Si g n at ur e: 
D at e: 
Pri nt N a m e: 
Wit n e s s of Si g n at ur e

Wit n e s s of c o n s e nt pr o c e s s



Consent and Authorization Form 
ADDITIONAL OPTIONAL CONSENT
TUMOR BIOPSY & BLOOD COLLECTION
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 1 of 9
Initials ________
Consent for Optional Subsequent Tumor Biopsies
and Blood Collection (if relevant to the main study)
Principal Investigator:
Antonio Jimeno, MD
COMIRB No:
14-0842
Version Date:
June 1, 2017
Study Title:
Pilot Study of Tissue and Hematopoietic/Mesenchymal Stem Cell Collection for 
Humanized Xenograft Studies in Melanoma and Squamous Head and Neck 
Cancer
You are being asked to be in an optional research study.  This form provides you with 
information about the study. A member of the research team will describe this study to you and 
answer all of your questions. Please read the information below and ask questions about 
anything you don’t understand before deciding whether or not to take part. 
Why is this study being done?
You are being asked to be in this optional research study because:
1.
You signed the main Informed Consent and Authorization Form and are taking 
part in the main part of this study. 
and
2.
You have started a new anti-cancer therapy as part of your regular clinical 
care for melanoma or head and neck squamous cell cancer (HNSCC) that is 
relevant to the main part of this study. 
This optional study plans to learn more about melanoma and head and HNSCC.  We are asking 
if you would be willing to provide research tumor biopsies and blood donations as another part 
of the research being conducted with this study. We want to analyze the additional research 
samples collected after you started a new therapy that is relevant to the main study. 
The testing we will do on this tissue is the same as the testing done on the original sample you 
provided us. That testing may include putting the tissue in mice (humanized model) to compare 
the samples, and to study the protein and genetic profiles of different tumor cells.  
Other people in this study
Up to 40 people from your area will participate in the study. 
COMIRB
APPROVED
For Use
14-Jun-2017
13-Jun-2018


Consent and Authorization Form 
ADDITIONAL OPTIONAL CONSENT
TUMOR BIOPSY & BLOOD COLLECTION
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 2 of 9
Initials ________
What happens if I join this study?
If you join the study, you will be asked to read and sign this consent form before study 
procedures would begin.
Study Procedures: 
We will collect the following research samples relevant to the main study:
o
Blood Samples – every 21 days (for the duration of anti-cancer therapy)
o
Tumor Tissue Biopsies 

Before starting any therapy

21 days after starting any therapy
If you agree to participate in this study, information about your diagnosis, medical history, 
disease, and treatment will also be collected.  This information will be linked to your tumor 
tissue so the study doctors have a better understanding of how these tests affect patient 
outcome.   
Your sample will only be used for research and will not be sold. However, the research done 
with your samples, derivatives or extracts may help to develop new products or ideas in the 
future. There is no plan for you to share in any financial gains.
We would also like to keep a sample of tissue from your tumor frozen (cryopreserved) for 
future research called “banking”. Future banking is another optional procedure and you will 
be asked below if you want to participate in this optional part of this study. 
Optional Procedure: 
Optional Consent for Data and Specimen Banking for Future Research
Dr. Antonio Jimeno would like to keep some of the data, blood and tissue that is 
taken during the study but is not used for other tests. If you agree, the data and 
samples will be kept and may be used in future research to learn more about 
melanoma and head and neck squamous cell cancer (HNSCC). The research 
that is done with your data and samples is not designed to specifically help you. 
It might help people who have melanoma and HNSCC and other diseases in the 
future. Reports about research done with your data and samples will not be given 
to you or your doctor. These reports will not be put in your health records. The 
research using your data and samples will not affect your care.
The choice to let Dr. Antonio Jimeno keep the data and samples for future 
research is up to you. No matter what you decide to do, it will not affect the care 
that you will receive as part of the study. If you decide now that your data and 
samples can be kept for research, you can change your mind at any time and 
contact your study doctor to let him or her know that you do not want Dr. Antonio 
Jimeno to use your data and samples any longer, and they will no longer be used 


Consent and Authorization Form 
ADDITIONAL OPTIONAL CONSENT
TUMOR BIOPSY & BLOOD COLLECTION
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 3 of 9
Initials ________
for research. Otherwise, they may be kept until they are used up, or until Dr. 
Antonio Jimeno decides to destroy them. 
When your data and samples are given to other researchers in the future, Dr. 
Antonio Jimeno will not give them your name, address, phone number or any 
other information that will let the researchers know who you are. 
Sometimes data and samples are used for genetic research (about diseases that 
are passed on in families). Even if your data and samples are used for this kind 
of research, the results will not be told to you and will not be put in your health 
records. Your data and samples will only be used for research and will not be 
sold. The research done with your data and samples may help to develop new 
products in the future, but there is no plan for you to be paid.
The possible benefits of research from your data and samples include learning 
more about what causes melanoma and HNSCC and other diseases, how to 
prevent them and how to treat them. The greatest risk to you is the release of 
your private information. Dr. Antonio Jimeno will protect your records so that your 
name, address and phone number will be kept private. The chance that this 
information will be given to someone else is very small. There will be no cost to 
you for any data or sample collection and storage by Dr. Antonio Jimeno.
Please read each sentence below and think about your choice. After reading 
each sentence, circle “yes” or “no.” If you have questions, please talk to your 
doctor or nurse. Remember, no matter what you decide to do about the storage 
and future use of your data and samples, you may still take part in the study.
I give my permission for my data and tissue to be stored in a central tissue bank 
at the University of Colorado for future use by the study investigators:
1.
I give my permissions for my data, blood and tissue samples to be 
kept by Dr. Antonio Jimeno for use in future research to learn more 
about how to prevent, detect, or treat melanoma and HNSCC.
   Yes
   No
_________Initials
2.
I give my permissions for my data, blood and tissue samples to be 
used for research about other health problems (for example: causes 
of heart disease, osteoporosis, diabetes).
   Yes
   No
_________Initials
3.
I give my permission for my study doctor (or someone he or she 
chooses) to contact me in the future to ask me to take part in more 
research.
   Yes
   No
_________Initials


Consent and Authorization Form 
ADDITIONAL OPTIONAL CONSENT
TUMOR BIOPSY & BLOOD COLLECTION
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 4 of 9
Initials ________
If you decide to withdraw your consent for the optional parts, you can continue to take part in the 
main part of this study, unless you withdraw your consent for the main part of the study as well.  
At the end of this consent form, you will also be asked to allow information collected from your 
optional specimen donations to be used. You need to agree to have information from these 
optional procedures to be used, or you cannot take part in these optional study procedures.
What are the possible discomforts or risks?
Discomforts you may experience while in this study include:
Risks of Having Blood Taken
At different points during this study we will need to get about 2 teaspoon of blood from you. 
We will get blood by putting a needle into one of your veins and letting the blood flow into a 
glass tube.  You may feel some pain when the needle goes into your vein.  A day or two 
later, you may have a small bruise where the needle went under the skin. 
Risk of Having a Tumor Biopsy
In this study we will need to have one or more small sample(s) of your tumor.  This 
procedure is called a “biopsy.”  Before we take the sample(s), we will give you some 
medicine to numb the area.  We will then make a small cut in your skin and take the 
sample(s) by pressing a hollow needle into your tumor tissue. When we take the needle out, 
it will remove a small circle of your tumor tissue called a “plug.”   
There are some risks to taking a sample of tumor tissue in this way.  There is a small 
chance that taking a sample of tumor tissue this way could cause an infection where the 
needles go in. You could also have an allergic reaction to the numbing medicine.  But this is 
rare.  After your skin heals up, you may have a small scar where we took the sample. 
Risk of Loss of Confidentiality
There is a risk that people outside of the research team will see your research information.  
We will do all that we can to protect your information, but it can not be guaranteed.
Other possible risks include:
If you become pregnant, the particular treatment or procedures involved in the study may 
involve risks to the embryo or fetus which are currently unclear. 
The study may include risks that are unknown at this time. 
What are the possible benefits of the study?
This study is designed for the researcher to learn more about melanoma and HNSCC.  


Consent and Authorization Form 
ADDITIONAL OPTIONAL CONSENT
TUMOR BIOPSY & BLOOD COLLECTION
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 5 of 9
Initials ________
This study is not designed to treat any illness or to improve your health.  Also, there may be 
risks, as discussed in the section describing the discomforts or risks.
.
Who is paying for this study? 
This research is being sponsored by the University of Colorado, National Institutes of Health 
and National Cancer Institute.
Will I be paid for being in the study?  
You will not be paid to be in the study. 
You may be eligible for travel, meal and/or lodging reimbursement.  Talk to the study team for 
more information.
Will I have to pay for anything?
It will not cost you anything to be in the study. 
The University of Colorado will pay for all treatments and medicines you will get in this study. 
You will not have to pay for any medical care that is part of this study. 
Is my participation voluntary?
You do not have to be in this study if you do not want to be.  Even if you decide to be in this 
study, you can change your mind and stop at any time.  If we learn new information that might 
make you want to leave this study, we will tell you about it. 
If you leave this study, you will not lose any of the benefits that you would normally get outside 
of this study.  Leaving this study will not affect your employment status or your reputation.  
Leaving this study will not change your ability to get government assistance.  If you leave this 
study, the only benefits that you will lose are the ones you are getting as part of this study.
Can I be removed from this study? 
You may be taken out of this study if the study doctor thinks it is not safe for you to be in the 
study.  You can be taken out of the study even if you do not want to leave the study. Also, the 
University of Colorado can decide to stop the study at any time.
If you are taken out of this study, you will not lose any of the benefits that you would normally 
get outside of the study.  Being taken out of the study will not affect your employment status or 
your reputation.  Being taken out of the study will not change your ability to get government 
assistance.  If you are taken out of the study, the only benefits you will lose are the ones you are 
getting as part of this study.
What happens if I am injured or hurt during the study? 


Consent and Authorization Form 
ADDITIONAL OPTIONAL CONSENT
TUMOR BIOPSY & BLOOD COLLECTION
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 6 of 9
Initials ________
If you have an injury while you are in this study, you should call Dr. Antonio Jimeno immediately. 
His phone number is 720-848-1543 or 720-848-0000 (24 hour contact number, ask for the 
medical oncology fellow on-call). 
We will arrange to get you medical care if you have an injury that is caused by this research.  
However, you or your insurance company will have to pay for that care. 
Who do I call if I have questions?
The researcher carrying out this study is Dr. Antonio Jimeno. You may ask any questions you 
have now. If you have questions, concerns, or complaints later, you may call Dr. Antonio Jimeno 
at 720-848-1543. You will be given a copy of this form to keep.  
You may have questions about your rights as someone in this study. You can call Dr. Antonio 
Jimeno with questions.  You can also call the responsible Institutional Review Board (COMIRB).  
You can call them at 303-724-1055. 
Who will see my research information?
The University of Colorado Denver (UCD) and its affiliated hospital(s) have rules to protect 
information about you. Federal and state laws including the Health Insurance Portability and 
Accountability Act (HIPAA) also protect your privacy. This part of the consent form tells you 
what information about you may be collected in this study and who might see or use it.  
The institutions involved in this study include:

University of Colorado Denver

University of Colorado Hospital
We cannot do this study without your permission to see, use and give out your information.  You 
do not have to give us this permission. If you do not, then you may not join this study.  
We will see, use and disclose your information only as described in this form and in our Notice 
of Privacy Practices; however, people outside the UCD and its affiliate hospitals may not be 
covered by this obligation.
We will do everything we can to maintain the confidentiality of your personal information but 
confidentiality cannot be guaranteed. 
The use and disclosure of your information has no time limit. You can cancel your permission to 
use and disclose your information at any time by writing to the study’s Principal Investigator (PI), 
at the name and address listed below. If you do cancel your permission to use and disclose your 
information, your part in this study will end and no further information about you will be 
collected. Your cancellation would not affect information already collected in this study.  
Antonio Jimeno, MD, PhD
University of Colorado Denver 


Consent and Authorization Form 
ADDITIONAL OPTIONAL CONSENT
TUMOR BIOPSY & BLOOD COLLECTION
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 7 of 9
Initials ________
University of Colorado Cancer Center
P.O. Box 6511
Campus Box 8117
Aurora, Colorado 80045
Both the research records that identify you and the consent form signed by you may be looked 
at by others who have a legal right to see that information, such as:  

Federal offices such as the Food and Drug Administration (FDA) and the Office of 
Human Research Protections (OHRP) that protect research subjects like you.

People at the Colorado Multiple Institutional Review Board (COMIRB)

The study doctor and the rest of the study team.

The University of Colorado, the entity who is paying for this research study.

Officials at the institution where the research is conducted and officials at other 
institutions involved in this study who are in charge of making sure that we follow all of 
the rules for research
We might talk about this research study at meetings.  We might also print the results of this 
research study in relevant journals.  But we will always keep the names of the research 
subjects, like you, private. 
You have the right to request access to your personal health information from the Investigator. 
Some of the research procedures involve genetic testing or the use of your genetic information.  
Your genetic information will not be released to others.  
Information about you that will be seen, collected, used and disclosed in this 
study:

Name and Demographic Information (age, sex, ethnicity, address, phone number, etc.).

Your social security number

Portions of your previous and current Medical Records that are relevant to this study, 
including but not limited to Diagnosis(es), History and Physical, laboratory or tissue 
studies, radiology studies, procedure results

Research Visit and Research Test records

Blood and Tissue samples and the data with the samples. 

Billing or financial information
What happens to Data, Tissue, Blood and Specimens that are collected in this 
study?
Scientists at the University of Colorado Denver and the hospitals involved in this study work to 
find the causes and cures of disease.  The data, tissue, blood and specimens collected from 
you during this study are important to this study and to future research.  If you join this study:


Consent and Authorization Form 
ADDITIONAL OPTIONAL CONSENT
TUMOR BIOPSY & BLOOD COLLECTION
Combined Biomedical Consent and Compound HIPAA authorization
CF-151.C, Effective 7-19-13
Page 8 of 9
Initials ________

The data, tissue, blood, or other specimens given by you to the investigators for this 
research no longer belong to you.  

Both the investigators and any sponsor of this research may study your data, tissue, 
blood, or other specimens collected from you.

If data, tissue, blood, or other specimens are in a form that identifies you, UCD or the 
hospitals involved in this study may use them for future research only with your consent 
or Institutional Review Board (IRB) approval.

Any product or idea created by the researchers working on this study will not belong to 
you.

There is no plan for you to receive any financial benefit from the creation, use or sale of 
such a product or idea. 
HIPAA Authorization for Optional Additional Study Procedures 
In this form, you were given the option to agree to additional, optional research procedures.  
You must also give us your permission, under HIPAA rules, to use and disclose the information 
collected from these optional procedures, as described above.  
Some of these optional procedures may involve genetic testing or the use of your genetic 
information.  Your genetic information will not be released to others.
If you decline to give us permission to use and disclose your information, you cannot take part in 
these optional procedures, but you can still participate in the main study.  Please initial next to 
your choice:
_____ I give permission for my information, from the optional procedures I have agreed to 
above, to be used and disclosed as described in this section.
_____ I do not give permission for my information for any optional procedures to be used 
and disclosed; I understand that I will not participate in any optional procedures.
Agreement to be in this study and use my data
I have read this paper about the study or it was read to me.  I understand the possible risks and 
benefits of this study.  I understand and authorize the access, use and disclosure of my 
information as stated in this form.  I know that being in this study is voluntary.  I choose to be in 
this study: I will get a signed and dated copy of this consent form.
Signature: 
Date: 
Print Name: 


C o n s e nt a n d A ut h o ri z ati o n F o r m 
A D DI TI O N A L O P TI O N A L C O N S E N T
T U M O R BI O P S Y & B L O O D C O L L E C TI O N
C o m bi ne d Bi o me dical C o nse nt a n d C o m p o u n d HI P A A a ut h orizati o n
C F- 1 5 1. C, Effecti ve 7- 1 9- 1 3
Pa ge 9 of 9
I nitials _ _ _ _ _ _ _ _
C o n s e nt f or m e x pl ai n e d b y: 
D at e: 
Pri nt N a m e: 
I n v e sti g at or: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
D at e: 
I n v e sti g at or m u st si g n wit hi n 3 0 d a y s
If a p pli c a bl e, t h e si g n at ur e li n e f or wit n e s s b el o w i s r e q uir e d f or c o n s e nt of n o n-r e a di n g 
s u bj e ct s, d e ci si o n all y c h all e n g e d a d ult s, or c o n s e nt u si n g a s h ort  f or m.
Si g n at ur e: 
D at e: 
Pri nt N a m e: 
Wit n e s s of Si g n at ur e

Wit n e s s of c o n s e nt pr o c e s s



Consent and Authorization Form Approval
ADDITIONAL OPTIONAL TUMOR/TISSUE BIOPSY
Combined Biomedical Consent and Compound HIPAA authorization (Effective 7-19-13)
Page 1 of 8                              
     Initials: __________
Optional Research Tumor Biopsy (Non-Standard of Care) Consent Form
Principal Investigator:
Antonio Jimeno, MD
COMIRB No:
14-0842
Version Date:
 June 1, 2017
Study Title:
Pilot Study of Tissue and Hematopoietic/Mesenchymal Stem Cell Collection for 
Humanized Xenograft Studies in Melanoma and Squamous Head and Neck 
Cancer
You are being asked to be in an optional research study.  This form provides you with 
information about the study. A member of the research team will describe this study to you and 
answer all of your questions. Please read the information below and ask questions about 
anything you don’t understand before deciding whether or not to take part. 
Why is this study being done?
You are being asked to be in this optional research study because:
1.
You signed the main Informed Consent and Authorization Form and are taking 
part in the main part of this study. 
and
2.
You are NOT scheduled for any additional biopsies or resections as part of 
your regular clinical care for melanoma or HNSCC.
This optional study plans to learn more about melanoma and head and neck squamous cell 
cancer (HNSCC).  The testing we will do on this tissue is the same as the testing done on the 
original sample you provided us. That testing may include putting the tissue in mice (humanized 
model) to compare the samples, and to study the protein and genetic profiles of different tumor 
cells.  
Other people in this study
Up to 40 people will participate in this study.
What happens if I join this study?
If you join the study, you will be asked to sign and date this consent form before study 
procedures would begin. 
Study Procedures:  
1.
Tumor Biopsy: You will be asked to have a biopsy of your tumor. This biopsy will be 
done when it is feasible and safe to do so. This tumor tissue will be collected and stored 
at the University of Colorado until it is analyzed.
2.
Tissue Use for Research. We will use some of the tumor tissue that is collected for 
research studies as soon as the sample arrives in the laboratory.
COMIRB
APPROVED
For Use
14-Jun-2017
13-Jun-2018


Consent and Authorization Form Approval
ADDITIONAL OPTIONAL TUMOR/TISSUE BIOPSY
Combined Biomedical Consent and Compound HIPAA authorization (Effective 7-19-13)
Page 2 of 8                              
     Initials: __________
This study may include germline or genetic testing.  

Germline testing looks at a line or sequence of germ cells that have genetic material 
that may be passed to a child or may be present in your family. The results of this 
testing will not be placed in your medical record, given to your doctor or given to you.

Genetic Testing allows the genetic diagnosis of vulnerabilities to inherited diseases, 
such as cancer.  The results of this testing will not be placed in your medical record, 
given to your doctor or given to you.
If you agree to participate in this study, information about your diagnosis, medical history, 
disease, and treatment will also be collected.  This information will be linked to your tumor 
tissue so the study doctors have a better understanding of how these tests affect patient 
outcome.   
Your sample will only be used for research and will not be sold. However, the research done 
with your samples, derivatives or extracts may help to develop new products or ideas in the 
future. There is no plan for you to share in any financial gains.
We would also like to keep a sample of tissue from your tumor frozen (cryopreserved) for 
future research called “banking”. Future banking is another optional procedure and you will 
be asked below if you want to participate in this optional part of this study. 
Optional Procedure:  
Optional Consent for Data and Specimen Banking for Future Research
Dr. Antonio Jimeno would like to keep some of the data and tissue that is taken 
during the study but is not used for other tests. If you agree, the data and samples 
will be kept and may be used in future research to learn more about melanoma and 
head and neck squamous cell cancer (HNSCC). The research that is done with your 
data and samples is not designed to specifically help you. It might help people who 
have melanoma and HNSCC and other diseases in the future. Reports about 
research done with your data and samples will not be given to you or your doctor. 
These reports will not be put in your health records. The research using your data 
and samples will not affect your care.
The choice to let Dr. Antonio Jimeno keep the data and samples for future research 
is up to you. No matter what you decide to do, it will not affect the care that you will 
receive as part of the study. If you decide now that your data and samples can be 
kept for research, you can change your mind at any time and contact your study 
doctor to let him or her know that you do not want Dr. Antonio Jimeno to use your 
data and samples any longer, and they will no longer be used for research. 
Otherwise, they may be kept until they are used up, or until Dr. Antonio Jimeno 
decides to destroy them. 
When your data and samples are given to other researchers in the future, Dr. 
Antonio Jimeno will not give them your name, address, phone number or any other 
information that will let the researchers know who you are. 


Consent and Authorization Form Approval
ADDITIONAL OPTIONAL TUMOR/TISSUE BIOPSY
Combined Biomedical Consent and Compound HIPAA authorization (Effective 7-19-13)
Page 3 of 8                              
     Initials: __________
Sometimes data and samples are used for genetic research (about diseases that are 
passed on in families). Even if your data and samples are used for this kind of 
research, the results will not be told to you and will not be put in your health records. 
Your data and samples will only be used for research and will not be sold. The 
research done with your data and samples may help to develop new products in the 
future, but there is no plan for you to be paid.
The possible benefits of research from your data and samples include learning more 
about what causes melanoma and HNSCC and other diseases, how to prevent them 
and how to treat them. The greatest risk to you is the release of your private 
information. Dr. Antonio Jimeno will protect your records so that your name, address 
and phone number will be kept private. The chance that this information will be given 
to someone else is very small. There will be no cost to you for any data or sample 
collection and storage by Dr. Antonio Jimeno.
Please read each sentence below and think about your choice. After reading each 
sentence, circle “yes” or “no.” If you have questions, please talk to your doctor or 
nurse. Remember, no matter what you decide to do about the storage and future use 
of your data and samples, you may still take part in the study.
I give my permission for my data and tissue to be stored in a central tissue bank at 
the University of Colorado for future use by the study investigators:
1.
I give my permissions for my data and tissue samples to be kept by Dr. 
Antonio Jimeno for use in future research to learn more about how to prevent, 
detect, or treat melanoma and HNSCC.
   Yes
   No
_________Initials
2.
I give my permissions for my data and tissue samples to be used for research 
about other health problems (for example: causes of heart disease, 
osteoporosis, diabetes).
   Yes
   No
_________Initials
3.
I give my permission for my study doctor (or someone he or she chooses) to 
contact me in the future to ask me to take part in more research.
   Yes
   No
_________Initials
If you decide to withdraw your consent for the optional parts, you can continue to take part in the 
main part of this study, unless you withdraw your consent for the main part of the study as well.  
At the end of this consent form, you will also be asked to allow information collected from your 
optional specimen donations to be used. You need to agree to have information from these 
optional procedures to be used, or you cannot take part in these optional study procedures.


Consent and Authorization Form Approval
ADDITIONAL OPTIONAL TUMOR/TISSUE BIOPSY
Combined Biomedical Consent and Compound HIPAA authorization (Effective 7-19-13)
Page 4 of 8                              
     Initials: __________
What are the possible discomforts or risks?
Discomforts you may experience while in this study include: 
Risks of Having a Tumor Tissue Biopsy: 
In this study we will need to have one or more small sample(s) of your tumor.  This 
procedure is called a “biopsy.”  Before we take the sample(s), we will give you some 
medicine to numb the area.  We will then make a small cut in your skin and take the 
sample(s) by pressing a hollow needle into your tumor tissue. When we take the needle out, 
it will remove a small circle of your tumor tissue called a “plug.”   
There are some risks to taking a sample of tumor tissue in this way.  There is a small 
chance that taking a sample of tumor tissue this way could cause an infection where the 
needles go in. You could also have an allergic reaction to the numbing medicine.  But this is 
rare.  After your skin heals up, you may have a small scar where we took the sample. 
Risk of Loss of Confidentiality
There is a risk that people outside of the research team will see your research information.  
We will do all that we can to protect your information, but it cannot be guaranteed.
Other possible risks include:
The study may include risks that are unknown at this time. 
What are the possible benefits of the study?
This study is designed for the researcher to learn more about melanoma and HNSCC.
This study is not designed to treat any illness or to improve your health.  Also, there may be 
risks, as discussed in the section describing the discomforts or risks.
Who is paying for this study? 
This research is being sponsored by the University of Colorado, the National Institutes of Health 
and the National Cancer Institutes.
Will I be paid for being in the study?  
You will not be paid to be in the study. 
You may be eligible for travel, meal and/or lodging reimbursement.  Talk to the study team for 
more information.
Will I have to pay for anything?
The University of Colorado will pay for all treatments and medicines you will get in this study.  
You will not have to pay for any medical care that is part of this study.


Consent and Authorization Form Approval
ADDITIONAL OPTIONAL TUMOR/TISSUE BIOPSY
Combined Biomedical Consent and Compound HIPAA authorization (Effective 7-19-13)
Page 5 of 8                              
     Initials: __________
Is my participation voluntary?
You do not have to be in this study if you do not want to be.  Even if you decide to be in this 
study, you can change your mind and stop at any time.  If we learn new information that might 
make you want to leave this study, we will tell you about it. 
If you leave this study, you will not lose any of the benefits that you would normally get outside 
of this study.  Leaving this study will not affect your employment status or your reputation.  
Leaving this study will not change your ability to get government assistance.  If you leave this 
study, the only benefits that you will lose are the ones you are getting as part of this study.
Can I be removed from this study? 
You may be taken out of this study if the study doctor thinks it is not safe for you to be in the 
study.  You can be taken out of the study even if you do not want to leave the study.  Also, the 
University of Colorado can decide to stop the study at any time.
If you are taken out of this study, you will not lose any of the benefits that you would normally 
get outside of the study.  Being taken out of the study will not affect your employment status or 
your reputation.  Being taken out of the study will not change your ability to get government 
assistance.  If you are taken out of the study, the only benefits you will lose are the ones you are 
getting as part of this study.
What happens if I am injured or hurt during the study? 
If you have an injury while you are in this study, you should call Dr. Antonio Jimeno immediately. 
His phone number is 720-848-1543 or 720-848-0000 (24 hour contact number, ask for the 
medical oncology fellow on-call).
We will arrange to get you medical care if you have an injury that is caused by this research.  
However, you or your insurance company will have to pay for that care.
Who do I call if I have questions?
The researcher carrying out this study is Dr. Antonio Jimeno.  You may ask any questions you 
have now. If you have questions later, you may call Dr. Antonio Jimeno at 720-848-1543. You 
will be given a copy of this form to keep.  
You may have questions about your rights as someone in this study. You can call Dr. Antonio 
Jimeno with questions.  You can also call the Colorado Multiple Institutional Review Board 
(COMIRB).  You can call them at (303) 724-1055. 
Who will see my research information?
The University of Colorado Denver (UCD) and its affiliated hospital(s) have rules to protect 
information about you.  Federal and state laws including the Health Insurance Portability and 
Accountability Act (HIPAA) also protect your privacy. This part of the consent form tells you 
what information about you may be collected in this study and who might see or use it.  


Consent and Authorization Form Approval
ADDITIONAL OPTIONAL TUMOR/TISSUE BIOPSY
Combined Biomedical Consent and Compound HIPAA authorization (Effective 7-19-13)
Page 6 of 8                              
     Initials: __________
The institutions involved in this study include:

University of Colorado Denver

University of Colorado Hospital
We cannot do this study without your permission to see, use and give out your information.  You 
do not have to give us this permission.  If you do not, then you may not join this study.  
We will see, use and disclose your information only as described in this form and in our Notice 
of Privacy Practices; however, people outside the UCD and its affiliate hospitals may not be 
covered by this obligation.
We will do everything we can to maintain the confidentiality of your personal information but 
confidentiality cannot be guaranteed. 
The use and disclosure of your information has no time limit.  You can cancel your permission to 
use and disclose your information at any time by writing to the study’s Principal Investigator (PI), 
at the name and address listed below.  If you do cancel your permission to use and disclose 
your information, your part in this study will end and no further information about you will be 
collected.  Your cancellation would not affect information already collected in this study.  
Antonio Jimeno, MD, PhD
University of Colorado Denver 
University of Colorado Cancer Center
P.O. Box 6511
Campus Box 8117
Aurora, Colorado 80045
Both the research records that identify you and the consent form signed by you may be looked 
at by others who have a legal right to see that information, such as:  

Federal offices such as the Food and Drug Administration (FDA) and the Office of 
Human Research Protections (OHRP) that protect research subjects like you.

People at the Colorado Multiple Institutional Review Board (COMIRB)

The study doctor and the rest of the study team.

The University of Colorado, the entity who is paying for this research study.

Officials at the institution where the research is conducted and officials at other 
institutions involved in this study who are in charge of making sure that we follow all of 
the rules for research
We might talk about this research study at meetings.  We might also print the results of this 
research study in relevant journals.  But we will always keep the names of the research 
subjects, like you, private. 
You have the right to request access to your personal health information from the Investigator. 
Some of the research procedures involve genetic testing or the use of your genetic information.  
Your genetic information will not be released to others.


Consent and Authorization Form Approval
ADDITIONAL OPTIONAL TUMOR/TISSUE BIOPSY
Combined Biomedical Consent and Compound HIPAA authorization (Effective 7-19-13)
Page 7 of 8                              
     Initials: __________
Information about you that will be seen, collected, used, and disclosed in this 
study:

Name and Demographic Information (age, sex, ethnicity, address, phone number, etc.).

Your social security number

Portions of your previous and current Medical Records that are relevant to this study, 
including but not limited to Diagnosis(es), History and Physical, laboratory or tissue 
studies, radiology studies, procedure results

Research Visit and Research Test records

Blood and Tissue samples and the data with the samples. 

Billing or financial information
What happens to Data, Tissue, Blood and Specimens that are collected in this 
study?
Scientists at the University of Colorado Denver and the hospitals involved in this study work to 
find the causes and cures of disease.  The data, tissue, blood and specimens collected from 
you during this study are important to this study and to future research.  If you join this study:

The data, tissue, blood, or other specimens given by you to the investigators for this 
research no longer belong to you.  

Both the investigators and any sponsor of this research may study your data, tissue, 
blood, or other specimens collected from you.

If data, tissue, blood, or other specimens are in a form that identifies you, UCD or the 
hospitals involved in this study may use them for future research only with your consent 
or Institutional Review Board (IRB) approval.

Any product or idea created by the researchers working on this study will not belong to 
you.

There is no plan for you to receive any financial benefit from the creation, use or sale of 
such a product or idea. 
HIPAA Authorization for Optional Additional Study Procedures 
In this form, you were given the option to agree to additional, optional research procedures.  
You must also give us your permission, under HIPAA rules, to use and disclose the information 
collected from these optional procedures, as described above.  
Some of these optional procedures may involve genetic testing or the use of your genetic 
information.  Your genetic information will not be released to others.
If you decline to give us permission to use and disclose your information, you cannot take part in 
these optional procedures, but you can still participate in the main study.  Please initial next to 
your choice:
_____ I give permission for my information, from the optional procedures I have agreed to 
above, to be used and disclosed as described in this section.


C o n s e nt a n d A ut h o ri z ati o n F o r m A p p r o v al
A D DI TI O N A L O P TI O N A L T U M O R/ TI S S U E BI O P S Y
C o m bi ne d Bi o me dical C o nse nt a n d C o m p o u n d HI P A A a ut h orizati o n ( Effecti ve 7- 1 9- 1 3)
Pa ge 8 of 8                              
     I nitials: _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ I d o n ot  gi v e p er mi s si o n f or m y i nf or m ati o n f or a n y o pti o n al pr o c e d ur e s t o b e u s e d 
a n d di s cl o s e d; I u n d er st a n d t h at I will n ot p arti ci p at e i n a n y o pti o n al pr o c e d ur e s.
A gr e e m e nt t o b e i n t hi s st u d y
I h a v e r e a d t hi s p a p er a b o ut t h e st u d y or it w a s r e a d t o m e.  I u n d er st a n d t h e p o s si bl e ri s k s a n d 
b e n efit s of t hi s st u d y.  I u n d er st a n d a n d a ut h ori z e t h e a c c e s s, u s e a n d di s cl o s ur e of m y 
i nf or m ati o n a s st at e d i n t hi s f or m.  I k n o w t h at b ei n g i n t hi s st u d y i s v ol u nt ar y.  I c h o o s e t o b e i n 
t hi s st u d y: I will g et a si g n e d a n d d at e d c o p y of t hi s c o n s e nt f or m.
Si g n at ur e: 
D at e: 
Pri nt N a m e: 
C o n s e nt f or m e x pl ai n e d b y: 
D at e: 
Pri nt N a m e: 
I n v e sti g at or:  
D at e: 
I n v e sti g at or m u st si g n wit hi n 3 0 d a y s
If a p pli c a bl e, t h e si g n at ur e li n e f or wit n e s s b el o w i s r e q uir e d f or c o n s e nt of n o n-r e a di n g 
s u bj e ct s, d e ci si o n all y c h all e n g e d a d ult s, or c o n s e nt u si n g a s h ort  f or m.
Si g n at ur e: 
D at e: 
Pri nt N a m e: 
Wit n e s s of Si g n at ur e

Wit n e s s of c o n s e nt pr o c e s s
